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Abstract 
Natriuretic peptides have been shown to alter fluid balance and ion levels in many 
tissues throughout the body including the renal and cardiovascular systems1.  When atrial 
natriuretic peptide (ANP) binds to its receptor (NPR-A), a dimerization event causes the 
activation of cGMP, initiating an internal second messenger cascade.  Infusion of ANP 
causes improved hearing thresholds, theoretically stimulated by the secondary 
messengers initiated by the ANP pathway.  The specific location of a natriuretic peptide 
receptor, NPR-A, in the inner ear including the exact mechanisms of the pathway 
stimulated by ANP binding, is still largely unknown. 
This study was designed to test the hypothesis that (1) NPR-A is in the cells of the 
cochlea critical for the regulation of endolymph and ion balance and (2) NPR-A is co-
localized with the effector protein NKCC1, known for its role in the movement of 
potassium and other ions in the inner ear.   
Immunohistochemistry was performed on cryosections of cochlea collected from 
mice of normal hearing.  Quantitative reverse-transcriptase polymerase chain reaction 
was also performed on kidney and cochlea homogenates, as well as laser capture 
microdissected cells to determine the mRNA levels of NPR-A in specific tissues. 
NPR-A was localized to six cell types in the cochlea including marginal and basal 
cells of the stria vascularis, root cells of the spiral ligament, interdental cells and limbal 
fibrocytes of the spiral limbus, and spiral ganglion neurons.  NPR-A expression was 
found in gateways critical for K+ influx into a cellular network or efflux from a cell into 
the endolymph, a high K+ extracellular fluid unique to the cochlea.  Furthermore, NPR-A 
was also found in type I neurons that are critical for neurotransmission, implicating a 
regulatory role for ANP directly in the sensory pathway. 
NPR-A was intermittently co-localized with NKCC1 in the marginal and 
interdental cells, which are both exit points for K+ from the recycling system into the 
endolymph.  NKCC1 may be an effector in these cells responsible for K+ efflux into the 
endolymph, but is likely only one of several, as co-localization was sporadic.  In other 
cells where NPR-A was expressed, NKCC1 was clearly not the effector activated in the 
ANP pathway as no co-localization was observed. 
These studies provide novel information about the location of NPR-A in the 
cochlea and its relationship to other proteins, indicating a regulatory role for natriuretic 
peptides in both neurotransmission and K+ recycling in the mouse inner ear.  Globally, 
determining the location of NPR-A in the cochlea identifies cellular targets for future 
molecular study of ANP action and the mechanisms for its regulation of hearing 
thresholds. 
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Introduction 
Mechanics of Hearing 
 The cochlea is a sensory organ with a highly specialized composition of intensely 
hard bone matter surrounding a delicate morphology of membranes and cell types.  These 
tissues work together to convert a mechanical sound stimulus into a chemical signals that 
eventually trigger action potentials in the auditory nerve2.  The cochlea consists of three 
spiral-shaped tubes filled with fluids with specific ion concentrations.  Two of these 
tubes, the scala tympani and the scala vestibuli, contain perilymph: a high sodium, 
potassium solution similar to other extracellular fluids found in the body.  These two 
scalae act to propagate the vibrations of the stapes on the oval window to the basilar 
membrane, where traveling cause transduction of the signal by the hair sensory cells of 
the organ of Corti.  The scala media, which rests between the scala vestibuli and scala 
tympani contains endolymph, a high potassium solution.  There is a high positive 
electrochemical potential difference from the perilymph that encases the scala media 
called the endocochlear potential3. 
The specialized hair cells are highly specific in both structure and function.  In the 
human cochlea, there are 1 row of inner hair cells and 3-5 rows of outer hair cells resting 
on supporting cells and a membrane known as the basilar membrane.  Historically, von 
Békésy determined that it was the basilar membrane that vibrates in response to sound at 
specific locations in the cochlea for a given frequency, and that this movement causes 
transduction of the signal into the hair cells generating receptor potentials4.   
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When the basilar membrane vibrates, specialized ion channels known as the 
mechanoelectrical transducer (MET) channels are mechanically opened and potassium 
ions enter the hair cells (Fig. 1)5,6.  These channels are located at the tips of the stereocilia 
and in close proximity to the tectorial membrane (Fig. 1).  Once the hair cells are 
depolarized by the rapid K+ influx voltage-gated calcium channels such as CaV1.3 
become activated allowing for an influx of Ca2+ on the basolateral surface of the hair 
cells7,8.  This calcium influx leads to the release of neurotransmitters causing action 
potentials in the auditory nerve cells.  For example, inner hair cells release glutamate 
from the basolateral cell surface, stimulating the afferent nerve connections from type I 
spiral ganglion cells3.  This signal then travels along the auditory nerve to the brain.  
Alternatively, when outer hair cells undergo depolarization, prestin (a voltage-triggered 
protein embedded in the membrane) contracts the outer hair cell which amplifies the 
sound-induced vibrations of the basilar membrane3.  This outer hair cell amplification 
allows for the extreme threshold sensitivity experienced by mammals. 
Mechanotransduction is facilitated by the large electrochemical gradient between 
the endolymph and the hair cells known as the endocochlear potential (EP).  The 
endolymph has a large positive potential, roughly 80-120mV due to the flow of 
potassium ions (a concentration of ~150 mM).  This is in comparison to the negative 
potential in the surrounding cells, such as the hair cells, that have a potential of around -
50 mV to -70 mV and a much lower potassium concentration3,9.  This high potassium 
gradient is largely produced by Kir4.110, a potassium inward rectifying channel present in  
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the intermediate cells of the stria vascularis (Fig. 2), a specialized epithelial tissue that 
maintains the ionic concentration of the endolymph. 
	  
Figure	  1:	  Anatomy	  and	  potassium	  recycling	  in	  the	  scala	  media.	  Potassium	  ions	  flow	  into	  the	  inner	  and	  outer	  hair	  cells	  in	  the	  organ	  of	  Corti	  when	  mechanotransduction	  channels	  open.	  K+	  then	  recycles	  through	  the	  supporting	  cells/spiral	  ligament/stria	  vascularis/spiral	  limbus	  and	  back	  to	  the	  endolymph.	  This	  diagram	  is	  a	  cross	  section	  of	  the	  fluid	  filled	  scala	  media,	  showing	  portions	  of	  the	  scala	  tympani	  and	  scala	  vestibuli	  on	  either	  side.	  	  Note	  the	  stereocilia	  (small	  black	  lines	  on	  the	  apical	  surface	  of	  the	  hair	  cells	  near	  the	  tectorial	  membrane).	  The	  outer	  three	  hair	  cells	  are	  on	  the	  right,	  while	  the	  inner	  hair	  cell	  is	  on	  the	  left.	  	  Blue	  arrow	  depicts	  K+	  recycling	  through	  the	  outer	  sulcus	  (right)	  while	  the	  purple	  arrow	  represents	  K+	  recycling	  through	  the	  inner	  sulcus	  (left).	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Cochlear Anatomy 
 The anatomy of the cochlea has a complex morphology with specialized 
membranous and osseous labyrinths (Fig. 1).  Within the organ of Corti alone, there are at 
least 12 different cell types with unique structures and functions.  From an anatomical 
perspective, understanding the differences between regions of the cochlea is essential to 
understanding the functions of the different cell types.  Simplistically, there are five main 
regions, the spiral limbus, the spiral ganglion, the organ of Corti, the spiral ligament, and 
the stria vascularis. 
Spiral Limbus 
 The limbus spiralis is both boney and membranous, where the term “spiral 
limbus” refers only to the membranous portion of the tissue11.  The membranous portion 
is derived from connective tissue and functions mainly to secrete the tectorial membrane 
and serve as an anchorage point for Reissner’s membrane (the membrane that separates 
the scala media from the scala vestibuli11).  The spiral limbus is composed of two cell 
types: the limbal fibrocytes necessary for ion flow and the interdental cells that secrete 
the tectorial membrane11 and sequester ions from the limbal fibrocytes for export them 
into the endolymph12.  One study has defined two subtypes of interdental cells and three 
subtypes of limbal fibrocytes11, but for simplicity, these subtypes will not be 
distinguished in this thesis. 
  5 
Spiral Ganglion 
 The spiral ganglion consists of bipolar nerve cells that have spherical cell bodies 
and send projections both peripherally towards the hair cells and centrally composing the 
auditory nerve.  The cell bodies are surrounded by accessory cells known as Schwann 
cells that support neuronal function.  There are Type I and Type II spiral ganglion 
neurons that vary in location and function13.  Composing 95% of the spiral ganglion, 
Type I spiral ganglion neuron cell bodies are very large in size and are housed in the 
middle of the nerve bundle14.  Each one sends an afferent projection that contacts only 1 
inner hair cell15.  Lateral efferent neurons from the ipsilateral lateral superior olivary 
complex in the cochlear nucleus coalesce on these afferent terminals for feedback16.  
Functionally, type I spiral ganglion nerves carry the action potential from the inner hair 
cells to the brain. 
 Type II spiral ganglion neurons also possess spherical cell bodies, but they are 
much smaller in size and are housed around the outer portions of the spiral ganglion.  
Type II neurons have peripheral projections that synapse on multiple outer hair cells and 
there are large efferent projections from the medial superior olivary complex that directly 
contact the outer hair cells14.  These cells act mainly to send signals to the outer hair cells, 
causing the contraction event and amplification of the signal. 
Organ of Corti 
 Named for Alfonso Giacomo Gaspare Corti, the organ of Corti is the major 
sensory portion of the cochlea.  The organ of Corti contains many cells types with 
differing morphologies and functions (Fig. 1).  The main function of the organ of Corti is 
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to convert mechanical energy from the middle ear into an electrochemical response.  The 
organ of Corti contains specialized sensory cells known as hair cells.  Hair cells are 
divided into two separate types, one row of inner hair cells and three to five rows of outer 
hair cells.  The inner hair cells are more medial, and are responsible for 95% of the 
generation of action potentials.  Conversely, outer hair cells are more lateral and act to 
amplify the acoustic signal3.  Both hair cell types have afferent and efferent connections, 
however inner hair cells have primarily afferent connections, sending signals to the brain, 
and outer hair cells have mainly efferent connections receiving signals from the brain.  
Outer hair cells are unique in that they contain prestin in their membranes, a protein that 
allows for contraction of the cells upon depolarization17.  This ability allows for further 
amplification of the signal. 
 Other than the sensory cells, the organ of Corti is mainly composed of epithelial 
cells that act in a supporting role.  These include the inner phalangeal cells the inner hair 
cells rest on, the Deiter’s cells that the outer hair cells rest in, and the pillar cells which 
support the tunnel of Corti, a space between the inner and outer cells where the type II 
neurons cross3.  The supporting cells are all connected by a gap-junction network that 
does not cross the tunnel of Corti, creating two separate systems.  The organ of Corti ends 
laterally with Claudius’ cells and the outer sulcus cells (root cells).  Medially, the organ 
of Corti terminates with the inner sulcus cells, that merge into the cells of the spiral 
limbus11. 
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Spiral ligament and the gap junction network 
 The spiral ligament is the lateral attachment point for the basilar membrane and is 
embedded in the lateral wall of the cochlea (Fig. 1).  Mainly composed of different 
fibrocyte types, the spiral ligament acts to facilitate recycling of potassium ions from the 
organ of Corti back to the stria vascularis18.  In addition to fibrocytes, the spiral ligament 
contains root cells, sometimes called outer sulcus cells.  The root cells play a major 
functional role in the recycling of potassium ions from the organ of Corti back to the 
endolymph19.  The cell bodies of the root cells are embedded within the outer sulcus 
adjacent to Claudius’ cells of the organ of Corti18.  In addition to their cells bodies in the 
outer sulcus, the root cells extend laterally through the fibrocytes of the spiral ligament19.  
Root cells are connected to the epithelial cells of the organ of Corti via gap-junctions, but 
do not share these connections with the surrounding fibrocytes (an important separation 
in the recycling of K+). 
Stria vascularis 
 The stria vascularis (StV) is an epithelial tissue that lines the scala media on the 
lateral wall of the cochlea20 (Fig. 1).  This tissue is a major regulator of the ionic balance 
of endolymph that fills the scala media.  The StV consists of three cell layers: most 
medially, the marginal cells that face the endolymph; the intermediate cells; and the basal 
cells that separate the stria vascularis from the spiral ligament2,3 (Fig. 2). 
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Figure 2: Structure of the stria vascularis. 
Composed of three differentiated cell layers, the stria vascularis functions to maintain the 
endocochlear potential by recycling K+ back into the endolymph. Gap junctions are noted 
as open rectangles, while tight junctions are depicted as closed black boxes.  The flow of 
K+ from the spiral ligament into the endolymph is represented with grey arrows and is 
shown moving through different transporters and channels.  Note the voltage and K+ 
concentrations in each cellular area. 
Marginal Cells 
 Marginal Cells (MCs) make up the most medial portion of the stria vascularis and 
are directly in contact with the endolymph of the scala media.  MCs are hexagonal in 
shape and often covered with microvilli on the endolymphatic surface, particularly in the 
apical turn of the cochlea 21.  The apical surface (with microvilli) is slightly round, and 
bulges out towards the endolymph.  The basolateral surface consists of long projections 
that extend laterally toward the basal cells of the stria vascularis20, creating invaginations 
for increased surface area and absorptive capacity22 (Fig. 2).  MCs are apically connected 
by tight junctions that create a barrier between the endolymph and cells of the stria 
vascularis20. 
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One of the major functions of marginal cells is to pull K+ from the intrastrial 
space and export the ions back into the endolymph.  This function is performed by a 
variety of channels and transporters such as NKCC1, a sodium, potassium, 2-chloride 
symporter.  NKCC1 is located on the basolateral surface of the marginal cells and acts to 
transport K+ ions into the cell from the intrastrial space23.  In mice strains engineered to 
lack the gene Slc12a2 that codes for NKCC124, the scalae volume is decreased causing 
deafness.  This evidence indicates that the NKCC1 co-transporter is essential for the 
maintenance of proper sound propagation. Once the K+ is in the cell, it is exported out of 
the MCs by KCNQ1/KCNE1 channels back into the endolymph to re-establish the K+ 
gradient and the EP. 
Intermediate Cells 
 The highly specific shape of the MCs allows for the intermediate cells (ICs) to 
interdigitate among the MC basolateral projections.  ICs are intermingled between 
marginal cells of the stria vascularis and are critical to establishing the endocochlear 
potential (EP) of the scala media (Fig. 2).  ICs express the potassium inward rectifying 
channel Kir4.110.  Within the stria vascularis, Kir4.1 is only found in intermediate cells 
(Fig. 2), making Kir4.1 a good molecular marker for this cell type.  Kir4.1 is essential to 
moving potassium ions out of the intermediate cells into the intrastrial space25. 26,27.  A 
2002 study with Kir4.1 knock-out mice showed that deletion of Kir4.1 leads to a lack of 
endocochlear potential, reduced endolymphatic volume and potassium concentration, and 
diminished hearing ability10,25. 
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ICs are derived from neural crest tissue and contain melanosomes, giving the cells 
a dark appearance 20.   One study classifies intermediate cells as basal intermediate cells 
and upper intermediate cells.  This distinction indicates that basal intermediate cells 
interact with the basal cell layer of the StV, while upper intermediate cells interact only 
with the basolateral surface of the marginal cells20.  While this may be an important 
anatomical differentiation among intermediate cell types, there are currently no 
functional distinctions between intermediate cells.  Therefore for the sake of simplicity, 
this manuscript classifies intermediate cells as one cell type. 
Basal Cells 
The basal cells (BCs) in the stria vascularis compose a single layer of flat cells20 
adjacent to the fibrocytes in the spiral ligament20,28.  In rats29, cats30, guinea pigs22,29,31, 
and humans32, BCs have projections that extend medially towards the marginal cell layer.  
BCs are highly permeable to K+ and connected together by tight junctions composed of 
Claudin-11 to form a strong barrier at the base of the stria vascularis against the 
fibrocytes2,3.  The basal barrier acts to contain the large electrical potential of the 
intrastrial space9,26,33.  When Claudin-11 is knocked out, potassium concentration in the 
endolymph is not affected, but EP is drastically reduced from a normal level of ~80 mV 
to ~30 mV34.  Theoretically, this would be because the transporters/channels that 
maintain the EP are still viable, but the K+ is not sequestered in the stria vascularis, and 
leaks back into the underlying fibrocytes.  This implicates the important role the basal 
cells must play in compartmentalization and maintenance of the endocochlear potential 
[i.e. the barrier prevents K+ reflux back into the fibrocytes in the connective tissue gap-
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junction network].  This ensures the passive influx of potassium ions into the intrastrial 
space cannot dissipate once basally generated3. 
Potassium flow in the cochlea 
 As previously mentioned, the movement of potassium in the cochlea is critical to 
maintaining function, and is known as the potassium recycling system.  Once K+ enters 
the hair cells, it has to be removed in order for the cell to repolarize.  KCNQ4 (Kv7.4) is 
a K+ channel embedded in the basal pole of outer hair cells that removes K+ from outer 
hair cells3.  One of the major causes of human deafness (DFNA2) is a defect in this pore, 
which leads to outer hair cell degeneration35.  While the loss of the channel and its 
expression profile indicate Kv7.4 is critical to the movement of K+ out of the outer hair 
cells, it is not the only K+ channel integral to this process. 
 Once the K+ is removed from the hair cells, it enters a gap junction network and 
moves laterally through the outer sulcus system up to the stria vascularis (Fig. 1, right 
blue arrow) or medially through the inner sulcus system and out of the spiral limbus2,3 
(Fig. 1 left purple arrow).  Both of these recycling pathways are distinguished by two 
gap-junction networks: an epithelial gap-junction network and a connective tissue gap-
junction network.  Potassium movement through these systems will be discussed in the 
following two sections. 
Potassium Recycling in the Outer Sulcus 
In the outer sulcus K+ recycling system, the epithelial gap-junction network 
consists of the supporting cells of the organ of Corti, while the connective tissue gap 
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junction network spans the spiral ligament and is mainly comprised of fibrocytes2,19.  In 
the epithelial gap-junction network, K+ ions pass through KCC3 and KCC4 transporters 
which shuttle K+ ions into the Deiter’s cells that underlie the outer hair cells3,19,36.  Kir4.1 
is also expressed in the Deiter’s cells, supporting the influx of K+ ions into the epithelial 
cells2.  Once in the supporting cells, potassium ions flow laterally through a series of gap 
junctions from the Deiter’s cells to the outer sulcus cells2,37.  These gap junctions are 
comprised of two hemi-channels that form a pore between cells.  Composed of different 
connexins (Cx26, Cx30, Cx32), these gap junctions passively transport molecules and 
ions of < 1 kDa2. 
 Outer sulcus cells, often referred to as root cells, act as the transition point for K+ 
ions from the epithelial gap junction system into the connective gap-junction network.  
These cells branch from the outer sulcus laterally into the spiral ligament between the 
fibrocytes18.  There are no gap-junctions between root cells (epithelial gap junction 
network) and the fibrocytes of the spiral ligament (connective tissue gap junction 
network) meaning K+ cannot simply move through the cells along a gradient2,18,19. 
Therefore, fibrocytes must express transporters to move K+ ions into the connective 
tissue gap-junction network. 
 In addition to the projections from the root cells, the spiral ligament consists of 5 
fibrocyte types that are differentiated by their anatomical positioning, morphologies, and 
the transporters and channels they express.  There are many uptake proteins for K+ and 
similar cations in the fibrocytes that surround the root cells.  One of these is NKCC1, 
which acts to move 1 Na+, 1 K+, and 2Cl- ions into the fibrocytes23.  Directly abutting the 
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outer sulcus cell root projections (epithelial gap-junction network) are type II18 and type 
IV38 fibrocytes of the connective tissue gap-junction network.  These fibrocytes are 
connected to other fibrocytes of the spiral ligament via gap-junctions and extend upward 
to connect to the basal cells of the stria vascularis.  The cytoplasm in the fibrocytes is 
similar to perilymph, with a low K+ concentration around 5 mM and a potential near 0 
mV4,39.  This internal environment facilitates the movement of K+ towards the stria 
vascularis to encourage recycling of the ions back to the endolymph through the outer 
sulcus recycling system. 
Potassium Recycling in the Inner Sulcus 
Potassium ions can also move through the inner sulcus recycling system (Fig. 1), 
but the cell distribution is not as differentiated (in both the number of cell types and 
anatomical differences) as it is in the outer sulcus system. The functions of the cells in the 
inner sulcus system are much less distinct, and the physical connections between cell 
types are not as well defined.  The inner sulcus recycling system performs roughly the 
same task as the outer sulcus system, with limbal fibrocytes carrying out functions 
synonymous with the basal strial cells as well as fibrocytes (of the spiral ligament).  The 
observation that K+ recycles in more than one direction is relatively new, and therefore 
less is known about recycling in this system. 
Similar to the outer hair cells, inner hair cells move K+ out at their basal poles.  K+ 
is then taken up by KCC3 in inner phalangeal cells, which do not express KCC4 like the 
Deiter’s cells36.  Once in the inner phalangeal cells, K+ is in the epithelial gap-junction 
network along the medial inner sulcus.  The transition in cell type from inner sulcus cells 
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to limbal fibrocytes is somewhat unclear, but at some point there is a transition in cell 
type from epithelial cells to limbal fibrocytes11.  From there, interdental cells sequester 
cations from the underlying limbal fibrocytes, and export them out into the endolymph12, 
completing the K+ recycling system through the inner sulcus. 
Natriuretic Peptides 
Natriuretic peptides (NPs) and their receptors regulate sodium and potassium 
concentrations, blood volume, blood pressure, long bone growth, pulmonary 
hypertension, and ventricular hypertrophy1.  There are three types of NPs in mammals: 
atrial (ANP), b-type (BNP), and c-type (CNP) natriuretic peptides.  The three NPs are 
structurally similar, with a conserved internal ring-structure (Fig. 3).  The conserved 
sequence begins and ends with a cysteine residue (CFGxxxDRIxxxxGLGC where X 
stands for any amino acid and is different for each NP), allowing formation of a disulfide 
bridge, giving the protein a tertiary ring-shaped structure40 (Fig. 3).  The peptide “tails” 
that branch off the ring structure are unique to each NP.  In total, ANP has 28 amino 
acids and BNP has 32 amino acids.  CNP has two subtypes: a 53 amino acid peptide and 
a 22 amino acid peptide that has a much shorter amino acid chain branching from the 
internal ring1. 
The three receptors for natriuretic peptides--- NPR-A, NPR-B, and NPR-C--- are 
located in the inner ear as well as other tissues (such as the kidney and the heart1,41,42).  
NPR-A and NPR-B are structurally similar, in that they both have an intracellular 
guanylyl cyclase domain, which acts to generate cGMP43(Fig. 3).  NPR-A can bind ANP 
and BNP, NPR-B can bind CNP, and NPR-C can bind all three peptides1.  NPR-C does 
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not have an internal guanylyl cyclase domain, and unlike the other receptors, acts to 
degrade circulating NPs44,45 (Fig. 3). 
 
 
Figure 3: The three natriuretic peptides and their receptors. 
The three NPs (ANP, BNP, and CNP) with the conserved internal ring structure and 
disulfide bridge (top) and the three natriuretic peptide receptor proteins are shown. Note 
the lack of internal sequence expressed by the clearance receptor NPR-C (right).  NPR-A 
and NPR-B act to generate cGMP from GTP when an appropriate NP binds. The receptor 
affinity of each NP is shown by the straight black arrows. NPR-A can bind ANP and 
BNP, NPR-B can bind CNP, and NPR-C can bind all three peptides1,46. 
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When ANP binds to its receptor, NPR-A, an external change happens to initiate a 
secondary messenger cascade that likely affects hearing.  NPR-A and NPR-B consists of 
a external ligand binding domain (the active site for the appropriate NP), a membrane-
spanning region, and an internal kinase homology domain that suppresses a guanylyl 
cyclase domain on the carboxyl terminal of the protein44.  When ANP or BNP binds to 
NPR-A (Fig. 3), it causes “”molecular tightening” in response to the disulfide linkage of 
the incoming hormone, leading to homo-dimerization of the receptor protein44.  This 
dimerization facilitates the activation of the internal kinase homology domain by ATP, 
which inhibits the repression of the guanylyl cyclase domain.  The kinase homology 
domain can be phosphorylated at 4 serine and 2 threonine residues.  When the kinase 
homology domain is activated, a conformational change occurs in the internal guanylyl 
cyclase domain causing the conversion of guanosine triphosphate (GTP) to cyclic 
guanosine monophosphate (cGMP)46 (Fig. 3). 
The availability of the second messenger compound, cGMP, leads to activation of 
proteinkinase G (PKG), a compound critical in many tertiary messenger systems in 
different cell types.  PKG has many functions, but in regards to audition is hypothesized 
to regulate other proteins that could alter EP and lead to changes in hearing.  In the 
kidney, one hypothesis is that ANP acts via NPR-A to activate NKCC transporters, 
resulting in natriuresis1,47,48  Because of the key roles of potassium in audition, this raises 
the possibility that natriuretic peptides and their receptors are involved in the regulation 
of NKCC1 and other ion channels and transporters in the ear as well, thereby contributing 
to the regulation of hearing thresholds (Fig. 4). 
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Figure 4: Hypothesized ANP pathway in the cochlea. 
ANP binds to its receptor protein, in this case NPR-A. This causes a number of internal 
conformational changes, but ultimately jump-starts a second messenger cascade.  What 
happens in the pathway after the generation of PKG is unclear.  However, infusion 
information collected in our lab indicates systemic infusion of ANP causes a change in 
hearing thresholds, thus forming the end of the ANP pathway in the cochlea. 
 
 Previous work in our lab has shown that infusion of ANP improves hearing 
thresholds in mice of normal hearing.  Increasing ANP by infusion in normal mice leads 
to both measurable improvements in hearing and increases in cochlear cGMP49.  NPR-A 
knockout mice (a nonsense mutation in the gene that encodes the receptor) develop 
normal hearing, but experience a high frequency hearing deficit by early adulthood.  
Infusing ANP in these mice does not confer hearing recovery, presumably because there 
is no receptor for the hormone and therefore no internal changes in cGMP levels.  
Furthermore, cochlear cGMP levels in the NPR-A knockout mice are also decreased50.  
In other labs, NPR-A mRNA has been localized to the cochlea using in situ hybridization 
and RT-PCR, however, these finding do not give precise expression patterns of NPR-A in 
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specific cells/tissues 41,41,42,51–54.  This combination of results implies a critical regulatory 
role for ANP in the cochlea, and therefore we developed the following experiments to 
determine the location of the receptor (NPR-A) to learn which cells ANP may influence. 
Hypotheses  
The overarching goal of these studies is to understand the role of natriuretic 
peptides in the inner ear.  NPs are crucial regulators of fluid balance in other tissues and 
therefore, may be critical in the maintenance of endolymph and endocochlear potential.  
This study specifically looked for the precise location of an NP receptor, NPR-A, in the 
cochlea to determine if its location was specific to areas critical for fluid movement.  This 
study also examined the relationship of NPR-A to other proteins known to regulate fluid 
or ion movement in the cochlea such as NKCC1 and Kir4.1.  Furthermore, laser capture 
microdissection and quantitative reverse transcriptase polymerase chain reaction were 
also performed to learn more about the expression of these proteins in the cochlea. 
Hypothesis	  1: NPR-A is located in regions of the cochlea important for the regulation 
of endolymph ion composition. 
 Ion composition of the fluid bathing the hair cells is essential to the physiological 
process of hearing.  If NPR-A activation results in changes to the endolymph and 
endocochlear potential, NPR-A should be located in regions of the cochlea that regulate 
fluid or ion balance.  This hypothesis was broken into two components.  Aim A) 
identified the expression pattern of NPR-A in the cochlea, while aim B) used specific 
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markers for different cell layers of the StV to determine more specifically where NPR-A 
was expressed. 
Hypothesis	  2: NPR-A is co-localized with an effector, NKCC1 in the proposed ANP 
pathway. 
 Likely effectors in the proposed ANP pathway will be in extremely close 
proximity to NPR-A (co-localized).  There are several definitions for co-localization, one 
being expression of the proteins in the same cells, but not overlapping.  This manuscript 
refers to co-localization as the overlap of colors due to expression of the two proteins in 
the same region of the same cell in the same section (i.e. when yellow label is observed).  
One potential effector in the ANP pathway is NKCC1, which is located in the stria 
vascularis and the spiral ligament and acts to transport sodium, potassium, and chloride 
ions into the endolymph26.  Using standard immunohistochemical techniques, these 
experiments looked for the relationship between NPR-A expression and that of NKCC1.  
Co-localization of the two proteins would implicate NKCC1 as the effector in the ANP 
pathway, as it would be in such close proximity to NPR-A that it would be logical 
assume a role in the second messenger cascade. 
Experimental Design 
These experiments were designed to bridge the gap of knowledge between 
overlapping observations about the functional role of ANP in the cochlea and the location 
of its receptor, NPR-A.  Without providing a biochemical mechanism, our lab has shown 
that administering ANP causes a temporary improvement in hearing thresholds49 
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(unpublished).  Understanding the location of the receptor proteins is key to determining 
where ANP may be acting in the cochlea. All experiments were performed on CBA/J 
mice with normal hearing around 100 days of age.  CBA/J mice were used because they 
do not carry any recessive genes linked to age-related hearing loss55.  Therefore, CBA/J 
mice have the most sustainable hearing of any inbred mouse strain. 
Two techniques were used to determine the specific location of NPR-A in the 
cochlea.  One of these was immunohistochemistry, which uses antibody staining to 
visualize the specific location of proteins in a given tissue.  The other technique 
employed was the combination of laser capture microdissection (LCM) and quantitative 
reverse-transcriptase polymerase chain reaction (qRT-PCR).  LCM allows for isolation of 
specific cells from a tissue.  With qRT-PCR, cDNA was generated from extracted RNA 
and the NPR-A gene was amplified using specific primers to target the gene sequence.  
Both Immunohistochemistry and LCM/qRT-PCR show the expression of NPR-A in 
specific tissues and provide information about the location of NPR-A in the cochlea that 
has not previously been described. 
For each hypothesis, it was important to use experimental techniques that could 
determine the specific location of the desired protein within a given tissue.  
Immunohistochemistry allows for specific visualization of a chosen protein by using 
antibodies with precise binding profiles against a particular antigen expressed by the 
protein.  This technique allows researchers to visualize spatial differences of a protein’s 
expression pattern between different tissue types and different samples.  Furthermore, by 
selecting multiple antibodies against different proteins, researchers can observe the 
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specific relationships between two or more proteins, answering questions about 
expression patterns and overlapping functions in different tissues. 
There are several methods for fine tissue sectioning including cutting in a 
vibrating microtome, embedding in plastic, or sectioning in a cryostat.  Cryostat 
sectioning was chosen because of its quickness and ease of use.  Using a vibrating 
microtome requires the whole tissue block to be cut, and much more intensive tissue 
preparation.  Embedding in plastic is also a more involved procedure, where as 
cryosectioning provides a similar product without much difficulty. 
Immunohistochemistry involves the use of a primary antibody that is labeled with 
a secondary antibody containing a fluorescent tag. Alexa fluorescent secondary 
antibodies were chosen because they are negatively charged and hydrophilic allowing 
them to stick to tissues better.  Additionally, Alexa dyes are more fade resistant than 
other fluorescent secondary antibodies and produce more vivid colors under microscopy.  
Alexa fluorescent dyes are also more stable and less pH sensitive than other dyes 
commonly used in immunofluorescence; this prevents variations in expression levels due 
to pH manipulations.  Alexa fluor®s were chosen in 488 (green) and 568 (red) in order to 
perform double-labeling experiments to examine the relationship between more than one 
protein on an individual section. 
 Complimentary to the immunohistochemical experiments, laser capture 
microdissection (LCM) was used with quantitative reverse transcriptase polymerase 
chain reaction (qRT-PCR).  LCM allows for the isolation of a particular tissue type from 
other cells in its native environment.  By performing this technique in concert with qRT-
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PCR, the mRNA that was actively expressed at the time of collection (an inference to 
expressed proteins) in a sub-region or cell type (for example cortex vs. medulla of the 
kidney) were run against the NPR-A primers to determine expression levels.  After LCM, 
the RNA was extracted from the cell isolates, a cDNA copy generated, and PCR run to 
amplify the NPR-A gene to compare expression levels of NPR-A of specific tissue types 
within the kidney and cochlea. 
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Hypothesis	  1:	  NPR-­‐A	  is	  located	  in	  regions	  of	  the	  cochlea	  important	  
for	  the	  regulation	  of	  endolymph	  ion	  composition.	  
1a) Where is NPR-A in the cochlea? 
 For this portion of the hypothesis, two techniques were used to show NPR-A 
expression in the cochlea.  To determine the location of NPR-A in the cochlea using  
Immunohistochemical experiments 
 Antibody 1 Antibody 2 
Hypothesis 1: Where is NPRA in the cochlea 
A) NPR-A in cochlea Primary: anti-NPRA 
(Abcam) 
Secondary: Alexa 568 
 
N/A 
  Primary: anti-NPRA 
(Potter) 
Secondary: Alexa 568 
N/A 
B) NPRA in Intermediate cells Primary: anti-NPRA 
Secondary: Alexa 568 
Primary: anti-Kir4.1 
Secondary: Alexa 488 
Hypothesis 2: NPRA and Effectors 
A) NPRA and NKCC1 Primary: anti-NPRA 
Secondary: Alexa 568 
Primary: anti-NKCC1 
Secondary: Alexa 488 
Control Experiments 
A) Positive Control in the 
kidney 
Primary: anti-NPR-A 
Secondary: Alexa 568 
Primary: anti-NKCC1 
Secondary: Alexa 488 
B) Negative Control in muscle Primary: anti-NPR-A 
Secondary: Alexa 568 
Primary: anti-NKCC1 
Secondary: Alexa 488 
 
Table 1: Layout of immunohistochemical experiments with corresponding 
antibodies. 
Each immunohistochemical experiment consists of a primary antibody and a secondary 
antibody. Double labeling of the tissues requires secondary antibodies in different colors 
in order to determine co-localization.  For each experiment, the tissue type is listed (left) 
with the first label in the middle (primary antibody with corresponding secondary 
antibody) and the second label on the right.  Alexa fluorescent antibodies are listed by 
color respectively with 568 corresponding to a red wavelength and 488 as a green 
wavelength.  Additionally, Hoechst reagent was added to each secondary antibody 
dilution to show nuclear material.  This reagent was blue in the 405 wavelength. With 
every experiment, control sections were generated which received no primary antibody 
labels.  This was to reveal any non-specific binding of the secondary antibodies. 
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immunohistochemistry, two different primary antibodies to target NPR-A were applied 
on cochlear sections.  Anti-NPR-A polyclonal rabbit IgG antibody (Abcam) was tagged 
with a goat anti-rabbit secondary Alexa fluorescent antibody in red (Invitrogen) using 
Hoechst to show nuclear material in blue (Table 1).  This anti-NPR-A antibody targeted 
the N-terminal region of the NPR-A protein (amino acids 1-30).  Another anti-NPR-A 
antibody was used, that was developed in the lab of Dr. Lincoln Potter56.  This was also a 
rabbit polyclonal IgG antibody, but it targeted the C-terminal region of the NPR-A 
protein.  Both antibodies received the same fluorescent tag and blocking agents (Table 1). 
The location of NPR-A in the cochlea was further investigated by qRT-PCR using 
a forward and reverse primer specific to the NPR-A protein on cells extracted by laser 
capture microdissection.  The primers chosen selected for the NPR-A and GAPDH 
mRNA (Table 2).   
Primers 




NPR-A Left 5’-GTGAAACGTGTGAACCGGAA-3’ 2047-2154 bp 108 bases 
NPR-A 
Right 
5’-AGCTCCCACAAATCTGGTCA-3’   
GAPDH 
Forward 
5’-AGAACATCATCCCTGCATCC-3’ 676-785 bp 110 bases 
GAPDH 
Reverse 
5’-CACATTGGGGGTAGGAACAC-3’   
 
Table 2: Primers and PCR product information. 
NPR-A and GAPDH primers (Integrated DNA Technologies) showing base pair targets 
and amplicon sizes. Amplicon sizes were within the suggested protocols of the Rotor-
gene™ kit and all had a GC content of 50%. Additionally, all primers had a melting 
temperature at approximately 60°C. 
 
The NPR-A primers targeted the 2047th to the 2154th base pairs in the 4065 bp 
NPR-A gene using the reported sequences (Table 2).  This yielded an amplicon of 108 
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base pairs, a size within the guidelines suggested by the Rotor-gene™ kit, and had a GC 
content of 50%.  Also used were primers for GAPDH, a housekeeping gene.  These 
primers targeted the 676th to the 785th base pairs in the 1275 base pair gene using the 
reported sequences (Table 2).  Both primer sets produced amplicons just above 100 bps; 
this was confirmed by gel electrophoresis. 
1b) Which cells express NPR-A in the stria vascularis? 
 To determine the expression of NPR-A in the stria vascularis, an antibody specific 
to intermediate cells of the stria vascularis used in concert with the NPR-A primary 
antibody to perform a double-label experiment.  An anti-Kir4.1 goat polyclonal primary 
antibody (Santa Cruz Biotech) was used as a marker for intermediate cells of the stria 
vascularis (as it is only expressed in these cells of the StV (Fig. 2)).  This primary 
antibody was tagged with a chicken anti-goat secondary Alexa fluorescent antibody in 
green (Table 1).  Again Hoechst was used to show nuclear material in blue (Table 1).  
These experiments were performed as a double label experiment with the NPR-A 
antibody again in red (as in the individual NPR-A experiments). 
Hypothesis	  2:	  NPR-­‐A	  is	  co-­‐localized	  with	  an	  effector,	  NKCC1	  in	  the	  
proposed	  ANP	  pathway.	  
2a) What is the relationship between NPR-A and NKCC1? 
 Reflecting the larger goals of this study, in addition to determining the specific 
tissue distribution of NPR-A in the cochlea, it was important to understand its 
relationship to other proteins that may be involved in the second messenger cascade in 
the ANP pathway.  Because of the relationship of NPR-A to NKCC1 in the renal system 
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in regards to ion regulation, NKCC1 is a likely candidate for an effector that becomes 
activated by the NPR-A activation.  Anti-NPR-A polyclonal rabbit antibodies (Abcam) 
were tagged with secondary Alexa fluorescent antibodies against rabbit in red 
(Invitrogen).  Anti-NKCC1 polyclonal goat antibodies (Abcam) were tagged using a 
green Alexa fluorescent antibody against goat (Table 1) (the same green Alexa 
fluorescent antibody as in the Kir4.1 double label experiments). 
Control	  Experiments	  
A) Are NKCC1 and NPR-A in the kidney as reported? 
 To provide evidence that the primary antibodies against NPR-A and NKCC1 were 
binding to their antigens as designed, control experiments were performed on tissues 
other than cochlea.  The same antibodies used in the above experiments were used to 
stain kidney tissue taken from mice after fixation with 4% paraformaldehyde (Table 1).  
The location of NPR-A1,57–59 and NKCC148,60,61 has been well documented in the kidney 
and therefore, this experiment acted as a positive control.  All experiments used the same 
dilutions and procedures as the cochlear experiments to ensure comparability.  No-
primary controls that received the blocking agent during staining were performed to 
ensure the secondary antibodies were specific to the primary antibodies. 
B) Are NKCC1 and NPR-A in muscle tissue? 
 Again, the same procedures and antibodies as in the cochlear experiments were 
used on muscle tissue (quadriceps muscle).  This experiment acted as a negative control, 
as neither NPR-A nor NKCC1 have been reported in skeletal muscle.  As earlier, no-
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primary controls that received the blocking agent during staining were performed to 
ensure the secondary antibodies were specific to the primary antibodies. 
Methods 
CBA/J mice were obtained from Jackson laboratories and maintained in the 
breeding colony at the Duluth campus of The University of Minnesota Medical School.  
Studies were performed on mice with normal hearing approximately 100 days of age.  All 
procedures were approved by the University of Minnesota Institutional Animal Care and 
Use Committee. 
Tissue	  Collection	  and	  Sectioning	  
Perfusions 
Mice were anesthetized using 0.1 ml of ketamine (2.5 µg/µl)/xylazine (5 µg/µl) 
anesthesia.  Transcardial perfusions were performed in the fume hood on CBA/J mice 
with a 4% paraformaldehyde, 0.5% picric acid solution for approximately 10 minutes at a 
rate of 2.6 ml/min.  The solution was delivered to the mouse via a 24 gauge, 1-inch 
needle using an automated, pulsatile pump (Minipuls 2, Gilson Incorporated).  To begin 
the perfusion, the hair covering the chest plate of the mouse was removed.  To expose the 
heart, the thorax was pierced below the lowest rib on the right side and then cut away.  
The fixative was pumped through the system by inserting the needle into the base of the 
left ventricle of the heart.  Simultaneously, an outlet was created by snipping the right 
atria to prevent expansion of the tissues and bursting of the membranes during perfusion. 
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After completion of the perfusion, the kidney and quadriceps muscle were 
collected as control tissues.  These tissues were placed in a series of sucrose dilutions as 
described in Table 3 in preparation for sectioning.  To access the cochlea, the mouse was 
decapitated, and the skull and brain were removed.   The cochleae were then extracted 
from the skull base and placed in solutions for decalcification and preparation for 
sectioning (Table 3). 
Solution Time in Solution: 
Cochleae 
Time in Solution: 
Control tissues 
9.3% EDTA 16 hours n/a 
10% Sucrose 10 hours 16 hours 
20% Sucrose 14 hours 24 hours 
30% Sucrose 24 hours 24 hours 
 
Table 3: Solution timeline for experimental tissues. 
Solutions timeline for various tissues after paraformaldehyde perfusion including 
cochlea, kidney, and the quadriceps muscle. Each tissue was kept in separate jars with 
both cochlea kept in the same jar.  The kidney and muscle tissues did not need 
decalcification (EDTA) so they were put straight into the 10% sucrose solution. 
 
Cryostat Procedure 
A cryostat was used to cut the tissues into fine sections for staining62.  The tissues 
were imbedded in OCT media and sectioned at a thickness of 10 µm at -27° C.  Sections 
were collected on Superfrost Plus-one™ charged glass slides, fixed with heat for roughly 
5 minutes, and then stored at room temperature overnight in preparation for 
immunohistochemical staining.  Unused sections were then stored at -70° C for future 
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experiments.  Generally the immunohistochemical procedures were performed on freshly 
fixed tissue to ensure maximum immunoreactivity.  However, frozen sections were used 
as needed and did not show different labeling profiles. 
Immunohistochemistry 
The sections were first circled using a super PAP™ blocking pen and then 
incubated in a blocking agent specific to the secondary antibody.  For example, anti-
Kir4.1 was blocked in 10% normal chicken serum (NCS) because the secondary that was 
used was raised in a chicken.  A summary of antibodies and their blocking agents is 
shown below (Table 4). 
Primary and Secondary Antibodies with Blocking Agents 
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Table 4: Blocking agents with corresponding primary and secondary antibodies. 
Table showing primary antibodies with their appropriate blocking agents and secondary 
antibodies.  PB is 0.1 M phosphate buffer while PBS is 0.1 M phosphate buffer with 
saline.  Both solutions maintained the same pH of 7.4.  Each primary and secondary 
antibody was diluted in the corresponding blocking agent, an each secondary solution 
received Hoechst reagent to stain nuclear material (blue). All secondary antibodies were 
diluted to a 1:200 dilution in the appropriate blocking agent. 
 
Each section was incubated in the blocking agent for 30 minutes.  After, the 
blocking agent was removed, 100 µl/section of the primary antibodies were added and 
incubated in a humid environment overnight at 4° C.  No-primary antibody control 
sections received the blocking agent during this time period (instead of primary 
antibody).  The second day consisted of 3, 10 minute washes in fresh blocking agent 
followed by an hour incubation in the secondary antibody at 37.5° C (also in a humid 
environment).  Secondary antibodies were specific to the primary antibody being used to 
reduce cross-reactivity.  Secondary antibodies (Invitrogen) were tagged with either Alexa 
488 (green) or Alexa 568 (red).  12.5 µl Hoechst stain was also added to the 1:200 
secondary antibody solution and mixed in the blocking agent.  Hoechst reagent binds to 
nuclear material and is in the 405n m range of immunofluorescence, staining all nuclei in 
blue. 
 During double label experiments, after 1-hour incubation in secondary antibody, 
the slides were washed 3 times in 0.1M phosphate buffer (pH 7.4) then submitted to a 
second round of staining to label the other primary antibody on the same sections (during 
double label experiments).  Again, the procedure was repeated using the blocking agent 
specific to the primary antibody (Table 4), and a secondary antibody in the other color.  
Generally, the anti-NKCC1 staining in Alexa 488 chicken anti-goat was performed first, 
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followed by the anti-NPRA staining in Alexa 568 goat anti-rabbit, but the order did not 
seem to affect the results. 
Imaging 
 Fluorescent images were taken within a week of staining to ensure accurate 
depictions of the staining intensities observed.  Images were collected using a Zeiss LSM 
710 confocal laser-scanning microscope.  All images were collected using similar pin 
hole size, gain, laser power, and pixel lengths to ensure comparability to control sections 
and between experiments (Table 5). 
Confocal parameters 
Pin hole 90 
Gain Between 600-800 
Laser power 1.0 
Pixel dwell Between 0.5 to 6 µsec (varied depending on 
magnification and zoom) 
 
Table 5: Confocal parameters used for section imaging. 
All experiments (including control tissues) were imaged using relatively similar settings 
to ensure comparability among different sections.  Natural variability between animals 
necessitated changes in gain as some sections stained heavily while other sections stained 
only moderately.  Factors influencing this include success of the perfusion, natural 
protein expression levels, and the cut of the tissue. 
 
Tissue	  Harvesting	  
Laser Capture Microdissection 
 Laser capture microdissection (LCM) involved multiple steps including 
cryosectioning, dehydration and staining, and capturing of the tissues.  The first step, 
cryosectioning, was performed as described above using similar conditions to the 
cryosectioning used for the immunohistochemical procedures.  LCM was always 
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performed on fresh tissue, and because the RNA needed to be protected, the slides were 
kept at -20°C until staining with the Arcturus® Histogene® staining kit.  Furthermore, 
the LCM sections were not heat fixed or air-fixed overnight in order to protect the RNA 
in the tissues.  Cochlear sections were collected on Superfrost™ Excell™ microscope 
slides while the kidney sections were collected on Histogene® slides provided with the 
Histogene® staining kit.  Cochleae did not adhere well enough to the provided slides, 
inhibiting the LCM procedure; therefore another slide type was used. 
 After cryosectioning, the slides were stained using the Arcturus® Histogene® 
staining kit.  Initially, the slides were thawed on a Kim wipe for 30 seconds to warm 
them to room temperature and adhere the sections to the slides.  Following a 30 second 
dip in 75% ethanol, the slides were hydrated in dH20 for 30 seconds.  On a Kim wipe, the 
slides were horizontally positioned and the Histogene® stain was added for 20 seconds 
followed by another 30 second dip in dH20.  Next a series of 30-second emersions in 
graded ethanols was performed.  First, the slides were dipped in 75% ethanol, then 95% 
ethanol, finalized with 100% ethanol, each for 30 seconds.  This dehydrated the sections 
so that the polymer on the LCM cap would better adhere to the tissue.  Lastly, the slides 
were dipped in xylene for 5 minutes and then air dried in the fume hood for another 5 
minutes.  To protect the slides, they were stored in a desiccator until LCM was performed 
(under one hour).   
 To capture the tissue, the stained slides were blotted with an Arcturus® Prep 
Strip™ to remove any loose or folded areas and placed on the microscope stage, held in 
place by the vacuum slide holder.  A CapSure® Macro LCM cap was placed on the 
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placement arm and the sections were examined using the visualizer.  Hovering over the 
tissue, the arm [with cap] was lowered over the tissue to begin microdissection.  Proper 
adhesion to the cap requires the tissue to be flat and dry.  Once positioned, the PixCell 
II™ laser (Arcturus®) was activated with the tracking beam visible on the sections.  On a 
blank patch of slide, the beam was focused and adjusted to a size of 7.5 µm until a sharp 
edge was seen.  Using a laser power of 20 mW for 5 µsec with a focus size of 30 µm, the 
laser was repeatedly fired over the desired tissue region to pull it from the section.  After 
laser fire, the placement arm with cap was swung off the section and the extracted cells 
visualized.  Before and after pictures were taken to ensure similar size products were 
captured.  To place the cap in the 0.5 mL microcentrifuge tube (RNA/DNAse free) the 
provided insertion tool was used while allowing for transfer of the cap from the 
placement arm to the incubation tube without human/glove contact.  This protected the 
RNA samples adhered on the cap from contamination and foreign RNAses.  After LCM 
with a given cap was complete, the cap incubated in the extraction buffer of the 
PicoPure™ RNA Isolation kit at 42°C for 30 minutes.   
LCM was performed on tissues from 8 animals, with only 2 kidney medulla 
preparations eventually successful at qRT-PCR.  None in the cochlea experiments were 
successful at yielding quality RNA for qRT-PCR.  Cochlear sections were extremely hard 
to capture, most likely because the sections are inherently not flat (a requirement of 
LCM).  Ultimately, just 1 cochlear section yielded captured cells, but the RNA quality 
was too poor (an issue that will be discussed in a future section) to produce successful 
qRT-PCR data. 
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RNA was isolated from specific cell types extracted from the kidney and cochlea 
using laser capture microdissection (as previously described).  Using a PicoPure™ RNA 
isolation kit (Arcturus), RNA was extracted from individual cell types in both the kidney 
and the cochlea (Table 6). 
Tissue Type Cell Type 
Kidney Cortex 
Medulla 
Cochlea Spiral Limbus 
Stria Vascularis 
Spiral Ganglion 
Lateral Wall (negative control) 
 
Table 6: Laser capture microdissections from each tissue. 
Cochlear dissections were from the entire spiral limbus, a combination of the spiral 
ligament and stria vascularis, and the lateral wall.  Kidney microdissections were from 
the roughly equal sizes of cortex and medulla.  Cochlear extractions were difficult to 
collect, and only 1 animal of 8 yielded extractable cells. 
 
The LCM caps were incubated in 50 µl of the extraction buffer and heated to 42° 
C for 30 minutes.  After a 2 minute centrifugation at 800 x g, the tubes (with caps) were 
stored at -80°C until the RNA isolation was performed.  The caps were and the provided 
spin columns were incubated in conditioning buffer at room temperature for 5 minutes, 
and then spun at 16,000 x g.  During the centrifugation, nuclease-free 70% ethanol was 
added to the RNA samples and gently mixed via pipetting.  Multiple cap extractions were 
combined in one tube to ensure maximum RNA yield.  Once the column was prepped 
with the conditioning buffer, the RNA sample mixture was added.  In order to bind RNA 
to the filter, the tubes were centrifuged for 3 minutes at 100 x g, followed by a 30 second 
centrifugation at 16,000 x g to remove any liquid in the column.  Wash buffer 1 was 
added to the column, and spun at 8,000 x g for one minute.  Following this centrifugation, 
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wash buffer 2 was added, and the spin column was centrifuged for one minute at 8.000 x 
g.  Another round of wash buffer 2 was performed, spinning at 16,000 x g for two 
minutes and then again for one more minute.  This additional centrifugation ensured all 
of the wash buffer was removed before RNA elution. 
To elute the RNA, the spin filter was transferred to a clean, ½ ml microcentrifuge 
tube and elution buffer was added to the filter.  As instructed by the Arcturus kit, the 
elution buffer was gently pipetted directly in the filter column.  The elution buffer 
incubated on the filter column for 30 minutes at 42°C to increase the RNA yield.  After 
this incubation, the tube (still containing the filter column) was centrifuged at 1,000 x g 
to distribute the elution buffer to the filter.  A final centrifugation was performed at 
16,000 x g for one minute to elute the RNA.   
Tissue Homogenates 
 Homogenate tissue samples were taken from non-perfused animals to test the 
primer binding and the RT/qPCR procedures.  Both kidneys were isolated from 4 animals 
giving a total of 8 samples.  Cochlear homogenate samples were isolated from 3 animals.  
The samples went through a standard RNA extraction procedure.  For kidneys, 
approximately 80 mg of tissue were used, while whole cochleae were homogenized 
(naturally mouse cochlea weigh about 15-20 mg each).  On the whole, the RNA yields 
were much higher than the LCM samples, probably because LCM samples went through 
the sucrose solutions (Table 3) where the RNA had more time to degrade than the fresh 
tissue from the homogenates.  Also, the physical amount of tissue captured via LCM was 
much less than a homogenate sample. 
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Quantitative reverse-transcriptase polymerase chain reaction (qRT-PCR) was 
performed to ensure the unique staining pattern observed in the kidney and cochlea was 
actually specific to the NPR-A protein (by measuring mRNA levels).  After successful 
RNA isolation, UV spectroscopy (Nanodrop® ND-1000 Spectrophotometer) was 
performed to approximate the RNA concentration.  While this is standard practice for 
RNA isolation, the PicoPure™ kit notes that these methods may not be reliable for such 
low levels of RNA.  Immediately following this procedure, the samples were either 
stored at -80°C or kept on ice in preparation for the cDNA generation. 
To determine the quality of the RNA, 4 µl samples were sent to the University of 
Minnesota Genomics Center where a total RNA analysis with picogram sensitivity was 
performed using a 2100 bioanalyzer from Agilent Technologies Inc.  Of the 8 total LCM 
kidney samples collected (medulla and cortex from each), only 2 registered any RNA 
present in the sample.  Furthermore, cochlear spiral limbus and stria vascularis/spiral 
ligament samples from the 1 cochlea that was successfully microdissected (CBA 551) 
were also analyzed, with none yielding quality RNA. 
Quantitative	  Reverse-­‐Transcriptase	  Polymerase	  Chain	  Reaction	  
(qRT-­‐PCR)	  
 
Using a QuantiTect® Reverse Transcriptase Kit (QIAGEN), cDNA was 
generated from the isolated cells pulled from the LCM caps and tissue homogenates.  The 
kit begins with a genomic DNA (gDNA) wipeout reaction.  This reaction calls for up to 1 
µg of template RNA, as previously estimated by UV spectrophotometry.  To complete 
this reaction, 2 µl of the gDNA wipeout buffer was added to the template RNA and 
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RNase-free water for a total reaction volume of 14 µl.  This reaction was mixed on ice, 
and incubated in a circulating water bath at 42°C for 2 minutes.  During this time, the 
reverse-transcriptase reaction was prepared using Quantiscript™ reverse transcriptase 
that contained an RNase inhibitor, Quantiscript RT buffer™ at a 5x concentration that 
contained Mg++ ions and dNTPs, and RT primer mix™.  This reaction was mixed with 
the gDNA reaction mixture and incubated at 42°C for 30 minutes.  Once the cDNA was 
generated, the reaction was immediately added to a 95°C water bath to inactivate the 
reverse-transcriptase enzyme.  The samples were then stored on ice in preparation for the 
quantitative polymerase chain reaction. 
Using the Rotor-gene™ SYBR® Green kit (QIAGEN), the cDNA was run 
through quantitative polymerase chain reaction (qPCR) to amplify the NPR-A gene.  
GAPDH (glyceraldehyde 3-phosphate dehydrogenase), an enzyme involved in glycolysis, 
was also run as a housekeeping gene (as its native to most cells in the body) (Table 2).  
To perform the reaction, each tube contained 12.5 µl of 2x Rotor-gene™ SYBR® green 
PCR master mix, 1 µl of each primer (1:4 dilution of both NPR-A or both GAPDH), 
template cDNA generated using the QuantiTect kit, and RNase-free water for a total 
reaction volume of 25 µl.  Using a Rotor-gene® thermocycler, the entire reaction was 
preceded with a 5 minute activation step at 95°C.  The reaction was set to run 35 cycles 
of 5 seconds at 95°C to denature and 10 seconds at 60°C for extension and finalized with 
a melt curve analysis to check the specificity of the primers (Fig. 8). 
To confirm the primers were specifically binding to the targeted genes, a number 
of controls were performed.  First, to check that the correct product was being generated, 
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the PCR product was run on a 2% agarose gel (Fig. 5, left).  This confirmed that each 
amplicon was one product (band) of the targeted size (Table 2).  Second, standard curves 
were constructed to ensure the primers were producing products in a linear range (Fig. 5, 
right).  To generate the standard curves, different dilutions of cDNA were run using the 
same qPCR conditions as the experimental samples.  Essentially, samples with higher 
DNA concentrations should have higher Ct values than samples with lower amounts of 
DNA.  Standard curves were generated for both the NPR-A and GAPDH primer sets. 
 
Figure 5: Primer amplicon size and standard curves for GAPDH and NPR-A 
primers. 
Molecular ladder yielding products down to 100 bp were run with qPCR products from 
GAPDH and NPR-A on a 2% agarose gel. Both samples were from mouse kidney 
homogenates, CBA 612. Standard curves for the GAPDH (top right) and NPR-A (bottom 
right) primer sets showing the linear dilution curves for cDNA.  
 
Lastly, qPCR products were sent for sequencing to ensure the correct genes were 
amplified.  GoTaq® Green master mix was substituted for the 2x Rotor-gene™ SYBR® 
green PCR master mix and does not produce fluorescence during qPCR.  The products 
were gel extracted and run through a PCR clean up procedure in preparation for 
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sequencing.  This cDNA reaction was doubled from the standard 25 µl reaction to the 50 
µl to ensure enough product was made. The reactions were run through the standard 
qPCR run, without the final melt step.  25 µl of both the NPR-A and GAPDH products 
were run on a 2% agarose gel to visualize the amplicon.  Using standard kits, the gel 
products (both just over 100 bps) were extracted and melted, then run through the gel 
extraction kit.  These products were re-combined with the other half of the GoTaq® 
Green master mix product and run through a standard PCR clean up kit.  In preparation 
for sequencing, 12 µl of the product were combined with 1 µl of one diluted primer (4 
tubes in total, 1 for each primer) and sent to the University of Minnesota Genomics 
Center for DNA sequencing.  Of the 4 primer tests sent, both NPR-A primers and the 
GAPDH reverse primer yielded the correct product.  The DNA yields were low after 
PCR clean up, which may have caused the failure of the forward GAPDH primer. 
To analyze the qPCR results, raw Ct values were obtained from the Rotor-Gene™ 
software.  Only 1 run of each homogenate sample was performed, but for the LCM 
samples, Ct values from multiple runs were averaged for the following calculations.  
From the Ct values, mRNA concentrations were calculated using the linear regression 
equations from the standard curves for each primer set, and used to compute the ratio of 
the absolute NPR-A expression levels to the absolute GAPDH expression levels.  The 
relative expression of NPR-A to GAPDH mRNA concentration for each tissue [cochlear 
homogenates, kidney homogenates, and kidney medulla LCM] was determined (Fig. 9). 
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Results  
The results of these experiments provided novel information about the location of 
NPR-A in the cochlea, as well as its relationship to other proteins such as Kir4.1 and 
NKCC1.  NPR-A was found in regions of the cochlea critical to K+ recycling and fluid 
balance.  These areas included the root cells of the spiral ligament, interdental cells of the 
spiral limbus, and cells of the stria vascularis.  NPR-A was also found in spiral ganglion 
neurons pointing to its role in neurotransmission.  NKCC1 was found in the spiral 
ligament, where it did not co-localize with NPR-A.  NKCC1 did intermittently co-
localize with NPR-A in other regions such as the stria vascularis and the spiral limbus.  
NKCC1 did not label the spiral ganglion neurons.  Both antibodies labeled the tectorial 
membrane. 
Control	  Experiments	  
 Kidney and muscle samples served as positive and negative controls respectively 
for both NPR-A and NKCC1.  The heaviest NPR-A labeling was in the tubules and renal 
podocytes (glomeruli) of the cortex, although these techniques did not allow for 
differentiation between various tubules and collecting ducts (Fig. 6d).  NPR-A label was 
also observed in the blood vessels associated with the renal cortex (Fig. 6f).  
Additionally, some staining was observed in the medulla (Fig. 6e).  This labeling is 
consistent with previous reports of NPR-A expression in renal podocytes, blood vessels, 
tubules and collecting ducts63–65.  Analyzing our NKCC1 label, there was heavier staining  
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Figure 6: Positive controls showing NPR-A and NKCC1 expression in the kidney. 
A-B. Mouse kidney cross-sections from CBA 505.  A. Control image with no primary 
antibody. B. Experimental image with anti-NKCC1 (Abcam) with an Alexa fluor 488 in 
green showing NKCC1 expression in both the medulla and cortex. C. Control image of 
CBA 532 cortex with no primary antibody. D. Experimental image of CBA 532 cortex 
with anti-NPR-A (Abcam) labeled with Alexa 568 in red showing NPR-A expression in 
tubules (orange arrowheads), glomeruli (circled), and renal blood vessels (double 
arrowheads). E. Experimental image from CBA 505 showing both the cortex and medulla 
(outlined).  NPR-A expression was in renal blood vessels (double arrowheads), and areas 
of the medulla (grey arrowheads). F. CBA 521 kidney cortex double-labeled with NPR-A 
and NKCC1. NKCC1 expressing in tubules/collecting ducts (white arrowheads) and 
NPR-A expression in blood vessels (double arrowheads).  Note NPR-A was also 
expressed in tubules, but this was overshadowed by the green label of NKCC1 in double 
label images. 
 
in the cortex of the kidney with less staining in the medulla (Fig. 6b).  These results are 
also consistent with previous reports about NKCC1 expression in the kidney. 
The quadriceps muscle acted as a negative control because neither NKCC1 nor 
NPR-A have been reported in skeletal muscle66,67.  Neither protein was significantly 
expressed (Fig. 7).  
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Figure 7: Negative controls showing lack of NPR-A and NKCC1 expression in 
muscle tissue. 
Mouse muscle from CBA 518. A. Control image with no primary antibodies. B. 
Experimental double-label image with NPR-A in red and NKCC1 in green.  Both images 
show Hoechst reagent in blue indicating the presence of all cells.  Sections were taken 
from the quadriceps muscle of mice fixed with paraformaldehyde (same conditions as 
cochlear staining).  Note relative similarity between the control (A) image and 
experimental image (B).  NKCC1 and NPR-A have not been reported in skeletal muscle, 
and therefore the lack of staining indicates the primary antibodies are not binding to 
regions that do not express those proteins. 
Laser	  capture	  and	  qRT-­‐PCR	  
 
 Using the NPR-A and GAPDH primers, melt curves were produced, revealing 
binding of the primers to the cDNA gene template.  As shown (Fig. 8), cochlea and 
kidney homogenate samples, as well as LCM kidney medulla samples expressed NPR-A 
and GAPDH.  The 2 LCM samples that showed measurable bands from the RNA 
analysis were also the samples that produced amplicons during qPCR, as evident by clean 
and distinct melt curves.  These samples were also only from medulla, as none of the 
cortex samples produced enough RNA to generate a melt curve.  However, based on both 
the immunohistochemical results and the literature, kidney cortex does express NPR-A, 
so this observation was most likely due to the low quality/amount of RNA yield.  
Additionally, there were some LCM samples that did show GAPDH reactions in both the 
medulla and cortex (data not shown). 
 There was no significant difference in NPR-A expression between the cochlea 
and kidney homogenates relative to GAPDH (p = 0.50265, 2 sample t-test) (Fig. 9).  For 
the LCM medulla samples, mRNA recovery appeared to give qualitatively similar NPR-
A levels as kidney homogenates, although this observation is purely correlative (n = 2). 
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Figure 8: Melt curve analysis from kidney and cochlea homogenate and LCM 
kidney medulla samples. 
Melt curve analyses show that only one peak was generated for each primer set in all 
samples. In each panel, the left peak corresponds to the NPR-A primer set and the right 
peak to the GAPDH. A. Cochlea homogenates from 6 samples (611A did not produce an 
NPR-A melt curve, and only had a low GAPDH peak). B. Kidney homogenates from 8 
total kidneys, 4 separate animals. C. LCM samples from kidney medullas in two animals. 




Figure 9: Relative expression of NPR-A to GAPDH in three unique tissue samples. 
Values for each peak were calculated using the linear regression from the standard curves 
for each primer set. This graph represents the difference in relative expression of NPR-A 
to GAPDH absolute values (see methods).  The medulla peak does not have a standard 
error bar as it was composed of only 2 samples and statistical calculations were not 
applicable. 
 
Hypothesis	  1:	  NPR-­‐A	  is	  located	  in	  regions	  of	  the	  cochlea	  important	  
for	  the	  regulation	  of	  endolymphatic	  ion	  composition.	  
 
1a) Where is NPR-A in the cochlea? 
 Using fluorescent immunohistochemistry and confocal microscopy, NPR-A was 
found in multiple tissue types of the cochlea (Fig. 10).  These tissue types included type I 
spiral ganglion cells (1), interdental cells of the spiral limbus (2), root cells of the spiral 
  46 
ligament (3), and several cells of the stria vascularis (4) (Fig. 10).  No differences were 
noted between the basal and apical turns of the cochlea. 
 
Figure 10: NPR-A was found in four specific regions of the cochlea. 
Mouse cochlea of CBA 432 showing the 1.5 turns of the scalae in cross section. A. 
Control image with no primary antibody.  B. Experimental image with anti-NPR-A 
primary antibody.  Both sections were exposed to a secondary antibody of Alexa 568 
goat anti-rabbit (red) and Hoechst reagent (blue). Positive staining was found in 4 distinct 
areas including the (1) cell bodies and central/peripheral processes of the spiral ganglion, 
(2) interdental cells of the spiral limbus, (3) root cells of the spiral ligament, and (4) cells 




The spiral ganglion contains the cell bodies of the nerve fibers that travel from the 
hair cells into the modiolus of the cochlea to form the vestibulocochlear nerve.  NPR-A 
was found in both the cell bodies of the spiral ganglion and the central and peripheral 
projections (Figs. 10 and Fig. 11).  However, NPR-A was not found within the hair cells 
themselves, but only in the tectorial membrane.  Most of the label observed in the organ 
of Corti was of the nerve terminals of the peripheral processes.  NPR-A expression was 
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specific only to Type I spiral ganglion neurons and not found in the cell bodies found 
along the outside of the ganglion (the type II neurons).  NPR-A was also noted in the 
peripheral processes that communicate with inner hair cells (type I neurons), but was not 
noted crossing the basilar membrane and therefore not expressed in peripheral processes 
that communicate with outer hair cells (Type II spiral ganglion neurons). 
 
 
Figure 11: NPR-A was expressed in nervous tissue of the spiral ganglion. 
Mouse spiral ganglion cells. A. Control image from CBA 596 with no primary antibody.  
B. Experimental image from CBA 518 with anti-NPR-A primary antibody.  Both sections 
used a secondary antibody Alexa 568 goat anti-rabbit (red) label and Hoechst reagent 
(blue). The expression pattern of NPR-A was specific to the neurons and was not present 
in the surrounding boney tissue of the modiolus or the supporting cells.  Arrows in B 
indicate the expression of NPR-A in the cell bodies of Type I spiral ganglion cells (grey 
arrows), the peripheral processes heading towards the hair cells (grey arrowheads), and 
central processes heading towards the auditory nerve bundle in the modiolus (white 
arrowheads). 
Spiral Limbus 
NPR-A was expressed in the interdental cells that line the scala media (Fig. 12), 
including all three sub-types.  These cells are apically exposed to endolymph and act as 
an exit point for K+ from the epithelial gap-junction network (Fig. 1).  NPR-A expression 
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was localized to the entire cell body of the interdental cells, and not just one cellular pole.  
There was little staining in the other areas of the spiral limbus using the N-terminal 
antibody (Abcam).  Occasionally, slight staining was observed in the inner sulcus cells.  
However, this staining was much less bright and obvious than the staining within the 
interdental cells (Fig. 12).  As described by Spicer and Schulte (1998), the spiral limbus 
has three interdental cell types and two fibrocyte types11.  These N-terminal antibody 
stained all 5 of these subtypes, although no molecular marker was used to differentiate 
among the limbal subtypes. 
Spiral Ligament 
In the spiral ligament, NPR-A was found only in the root cells, and not expressed 
in any of the surrounding fibrocytes (Fig. 13).  Root cells line the curve of the 
membranous portion of the lateral wall (the outer sulcus), covering the transition from the 
basilar membrane to the spiral ligament proper.  These cells are apically exposed to 
endolymph, and have basolateral projections deep into the fibrocyte network of the spiral 
ligament18.  NPR-A specifically stained in both the cell body and root processes, being 
present throughout the entire cell. 
C-terminal (Potter) Antibody Staining 
Similar expression patterns were observed between the N-terminal (Abcam) and 
C-terminal (Potter) antibody labels, although there were some variances in intensities 
(Fig. 14).  The only major difference was in the staining of the spiral limbus, where the 
C-terminal (Potter) antibody exhibited staining in limbal fibrocytes as well as the 
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Figure 12: NPR-A was expressed in 
interdental cells of the spiral limbus. 
Sections from the spiral limbus in the 
mouse cochlea of CBA 596.  Arrows 
indicate the interdental cells in each 
panel.  A. Transmitted light image 
showing the spiral limbus tissue.  B. 
Control image with no primary 
antibody.  C. Experimental image with 
anti-NPR-A primary antibody.  All 
treatments have a secondary antibody 
of Alexa 568 goat anti-rabbit (red) and 
Hoechst reagent (blue). Note the outline 
around the tectorial membrane in each 
image, which is not stained when the 
primary antibody is not present (B). 
Interdental cells are indicated with 
white arrows, with limbal fibrocytes 
acting to support them. NPR-A was 
also expressed in the spiral ganglion 
(C) in both the cell bodies and 
peripheral processes that travel through 
Rosenthal’s canal towards the inner 
hair cells (arrowheads).  Possible label 
in the terminal buds of the neurons was 
also observed (asterisk). SLb spiral 
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Figure 13: NPR-A was in the root 
cells of the spiral ligament. 
Images of the spiral ligament from 
mouse cochlea. A. Transmitted light 
image showing the spiral ligament 
tissue from CBA 596. B. Control image 
with no primary antibody from CBA 
596. C. Experimental image with anti-
NPR-A primary antibody (red) from 
CBA 432. Note the intense expression 
pattern of NPR-A deep within the spiral 
ligament. (B/C) Both sections have a 
secondary antibody of Alexa 568 goat 
anti-rabbit (red) and Hoechst reagent 
(blue). Asterisk indicates the first and 
last root cell body along the outer 
sulcus of the spiral ligament. Note the 
expression of NPR-A in the strial basal 
cells. StV Stria vascularis. SLg Spiral 
ligament. LW lateral wall. 
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interdental cells as seen with the N-terminal (Abcam) antibody (Fig. 12).  The specific 
locations and degree of labeling observed with the two NPR-A antibodies are 
summarized (Table 7).  Due to the complicated morphology and expression patterns in 
the strial vascularis, they will be discussed in a later section. 
 





Spiral limbus Connective 
Interdental cells +++ ++  
Fibrocytes - ++  
Stria Vascularis Epithelial 
Marginal cells ++ +  
Intermediate cells - -  
Basal cells +++ +  
Spiral ligament Connective 
Root cells +++ ++  
Fibrocytes - -  
Spiral ganglion +++ ++ Nervous 
Tectorial membrane + + Connective 
Organ of Corti    
Hair cells - - Sensory 
Supporting cells - - Epithelial 
Basilar membrane - - Connective 
Reissner’s membrane - - Connective 
Lateral wall - - Bone 
Modiolus - - Bone 
 
Table 7: NPR-A was in regions of the cochlea specific to potassium recycling and 
neurotransmission. 
Specific tissue locations of NPR-A within the cochlea using two antibodies against 
different regions of the protein.  (+) denotes positive staining, with degree represented by 
number of signs. (-) indicates negative staining. Last column lists cell types of each tissue 
listed. Staining was occasionally observed in connective tissue such as the basilar and 
tectorial membranes, but not always observed. 
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Figure 14: NPR-A expression in the cochlea using the Potter antibody. 
A-F. CBA 518, 1:100 C-terminal antibody (Potter) against NPR-A. Similar expression 
patterns to the N-terminal NPR-A antibody (Abcam) were observed.  All sections used a 
1:200 secondary antibody Alexa 568 (red) goat anti-rabbit label and Hoechst reagent 
(blue). A-B. Grey circle for the collapsed cells of Reissner’s membrane with different 
scalae outlined with doted lines. A. Control image with no primary antibody. B. 
Experimental image showing NPR-A expression in the spiral limbus (SLb), spiral 
ganglion (SPG), spiral ligament (SLg), and stria vascularis (StV). Expression also noted 
in the tectorial membrane (TM). Asterisk indicates the organ of Corti. C. Mouse spiral 
ganglion showing expression in both the cell bodies and central and peripheral processes 
of the nerve cells.  Insert shows cropped image spiral ganglion cell bodies with NPR-A 
expression. D. Mouse stria vascularis with marginal cell (arrowheads) and basal cell 
(arrows) NPR-A expression. E. NPR-A expression in the cell bodies of the root cells of 
the spiral ligament (arrowheads) and their lateral projections (arrows). F. Experimental 
image showing the NPR-A expression in the spiral limbus (outlined). NPR-A was 
expressed in interdental cells as well as limbal fibrocytes. Note the non-specific staining 
in the tectorial membrane as well as the slight stain in the collapsed cells of the organ of 
Corti (asterisk). 
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A similar expression pattern was observed using both antibodies, although 
disparities in intensity were observed, as well as the differences in expression in the spiral 
limbus.  The dissimilarity of the two antibodies in the stria vascularis was not due to 
cellular localization, but was specific to the intensity of the stain.  Using the C-terminal 
antibody, both basal and marginal cells did not stain as vividly but label was clearly 
observed.  The N-terminal antibody (Abcam) staining was much stronger, but again was 
still found in the same areas as the C-terminal antibody.  Other regions in the cochlea did 
not show differences in staining using the two NPR-A antibodies. 
Stria vascularis 
NPR-A labeling was evident in the stria vascularis (Figures 10, 13, and 14).  
NPR-A was expressed along the basal pole of the basal cells as well as throughout the 
body of the marginal cells.  There was variability in the staining intensity with both NPR-
A antibodies noted within the intermediate layer of the stria vascularis, which made it 
unclear whether NPR-A was local only to marginal cells [and their projections] or within 
the intermediate cells themselves (that are interdigitated among the MC projections).  In 
order to determine the specific strial cell types that express NPR-A, the second portion of 
the hypothesis was developed. 
1b) Which cells express NPR-A in the stria vascularis? 
Because Kir4.1 is only expressed in the intermediate cells of the stria vascularis29, 
dual labeling with NPR-A was employed to determine whether NPR-A labeling was 
specific to this cell population in the stria vascularis.  Co-localization between NPR-A 
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and Kir4.1 (Fig. 15) was not observed suggesting that NPR-A was in the basolateral 
projections of marginal cells and not in the intermediate cells.  
 
Figure 15: NPR-A and Kir4.1 did not co-localize in the intermediate cells of the stria 
vascularis. 
Stria vascularis of the mouse cochlea from CBA 521. A. Control image with no primary 
antibodies. B. Experimental double-label image with anti-Kir4.1 (green) and anti-NPR-A 
(red) with Hoechst reagent (blue). No co-localization was observed, indicating NPR-A 
was not expressed in intermediate cells (white arrows), with any label in that area 
attributed to projections from the abutting marginal cells (grey arrowheads) or basal cells 
(white arrow heads). While the control image (A) showed low levels of green label, this 
was due slight non-specific binding of the secondary antibody (specific green label in B 
noted with white arrows). Inset shows the mid section of the stria vascularis. Note the red 
stain and green strain in the “middle” of the stria vascularis, lacking any yellow overlap. 
 
 To summarize, NPR-A was found in four distinct regions of the cochlea including 
the stria vascularis, the spiral ligament, spiral limbus, and spiral ganglion.  Using both the 
N-terminal (Abcam) and C-terminal (Potter) antibodies along with the double-labeling 
experiments of NPR-A with Kir4.1, NPR-A was in the marginal cells of the stria 
vascularis and the basal portion of the basal cells within the stria vascularis.  Looking at 
the spiral ligament, NPR-A was localized to the cell bodies and root processes of the root 
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cells, but not expressed in the surrounding fibrocytes.  Expression within the spiral 
ganglion showed NPR-A in the cell bodies and central/peripheral processes of Type I 
spiral ganglion cells, but not in the Type II spiral ganglion cells or Schwann cells.  Lastly, 
NPR-A was expressed in the interdental cells of the spiral limbus (both antibodies) and 
the limbal fibrocytes (C-terminal antibody) as summarized (Fig. 16). 
 
 
Figure 16: NPR-A expression in the cochlea. 
Summary diagram of the expression of NPR-A in the cochlea showing the specific 
regions positive for NPR-A labeling.  NPR-A was found in the marginal and basal cells 
of the stria vascularis, root cells of the spiral ligament, interdental cells (and limbal 
fibrocytes) of the spiral limbus, and spiral ganglion neurons.  Some label was also 
observed in the tectorial membrane. 
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Hypothesis	  2:	  NPR-­‐A	  is	  co-­‐localized	  with	  an	  effector,	  NKCC1	  in	  the	  
proposed	  ANP	  pathway.	  
2a) What is the relationship between NPR-A and NKCC1? 
 NKCC1 was expressed in the stria vascularis, spiral ligament, and spiral limbus 
(Table 8).  The relationship between NPR-A and NKCC1 was complex, in that some 
tissues showed co-localization, some showed segregated expression, and some NPR-A 
containing regions did not express NKCC1 at all (Table 8).  As previously stated, this 
thesis regards co-localization as any yellow color observed, theoretically due to the 
expression of both proteins in the same region of the same cell at the same time [co-
localization could also mean just in the same cell].  The spiral limbus contained the 
highest degree of co-localization, as interdental cells expressed both NPR-A and NKCC1.  
Moreover, there was some intermittent co-localization in some cells of the stria 
vascularis, however this was infrequent. 
Spiral limbus 
 Within the spiral limbus, NKCC1 was expressed more medially away from the 
inner sulcus.  NKCC1 was expressed in interdental cells and in central and medial limbal 
fibrocytes (Fig. 17).  However, NKCC1 and NPR-A intermittently co-localized within the 
interdental cells (both antibodies).  While this co-localization was often observed, it was 
not ubiquitous to every cell nor was it observed in every animal (Fig. 17).  For example, 
the spiral limbus shown in figure 18b shows less co-localization in the interdental cells 
than is shown in figure 17.  Co-localization was not observed in limbal fibrocytes using  
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Tissue type NPR-A Staining NKCC1 Staining 
(Abcam) 
Spiral limbus 
Interdental cells +++ ++ 
Limbal fibrocytes -(Abcam)/++(Potter) ++ 
Stria vascularis 
Marginal cells +++ ++ 
Intermediate cells - - 
Basal cells +++ - 
Spiral ligament 
Root cells +++ - 
Fibrocytes - ++ 
Spiral ganglion ++ - 
Tectorial membrane ++ ++ 
Organ of Corti   
Hair cells - - 
Supporting cells - - 
Basilar membrane - - 
Reissner’s membrane - - 
Lateral wall - - 
Modiolus - - 
 
Table 8: Summary of expression patterns of NPR-A and NKCC1 within the cochlea. 
NPR-A and NKCC1 were often expressed in similar regions of the cochlea, but rarely 
exhibited co-localization. NPR-A and NKCC1 intermittently co-localized in the 
interdental cells of the spiral limbus and the basolateral surface of the marginal cells in 
the stria vascularis. NPR-A and NKCC1 did not co-localize in the basal cells of the stria 
vascularis or the spiral ligament.  NKCC1 was not expressed in the spiral ganglion. (+) 
denotes positive staining, with degree represented by number of signs. (-) indicates 
negative staining. 
 
both the N-terminal antibody (Abcam) (Fig. 17) and the C-terminal antibody (Potter) 
(data not shown). 
Stria vascularis 
NKCC1 was expressed in the most medial layer of the stria vascularis, consistent 
with earlier observations that NKCC1 is found in the basolateral plasmalemma of the 
marginal cells in the StV20.  NPR-A and NKCC1 did co-localize in the marginal cell layer 
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in an intermittent expression pattern similar to the observations in the interdental cells of 
the spiral limbus (Fig. 18).  NKCC1 was expressed with less intensity through the 
intermediate cell layer of the StV, and was not found in the basal cells.  Staining was also 
observed abutting the basal cells, however this was likely due to the marginal cell 
projections, which extend all the way to the basal cells (Fig. 18c-e). 
 
Figure 17: Slight co-localization pattern of NPR-A and NKCC1 in the spiral limbus. 
Spiral limbus sections from the mouse cochlea.  A. Control image from CBA 297 with no 
primary antibodies.  B. Experimental image with anti-NPR-A primary antibody with 
secondary Alexa 568 (red).  C. Experimental image with anti-NKCC1 with the secondary 
Alexa 488 (green).  Both images have Hoechst reagent (blue).  D. Merged image from 
CBA 432 of the two secondary labels where yellow indicates regions of co-localization 
of the two proteins. Note the asterisk highlighting examples of the location of interdental 
cells on the endolymphatic surface of the spiral limbus. Inset shows specific interdental 
cells positive for both NPR-A and NKCC1 expression (yellow), with some exhibiting 
only one protein (green or red). 
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Figure 18: NKCC1 and NPR-A are occasionally expressed in the same cells within 
the stria vascularis. 
A-B. Scala media sections from CBA 518. A. Control image with no primary antibodies.  
B. Double-label image of the scala media with anti-NKCC1 (green) and anti-NPR-A 
(red) with Hoechst (blue). The asterisk indicates labeling in the tectorial membrane and 
collapsed cells from the organ of Corti. Circle indicates collapsed cells of Reissner’s 
membrane, with the proper location designated with the grey dotted line.  C-E. Inserts of 
the stria vascularis from CBA 518. Arrows indicate areas of co-localization between the 
two proteins. C. Anti-NKCC1 primary antibody (green). Mc marginal cells. Ic 
intermediate cells. Bc basal cells. D. Anti-NPR-A primary antibody (red). E. Merged 
double-label image exhibiting some regions of co-localization (yellow, arrows).  Note 
that the co-localization is infrequent and does not appear as a continuous yellow line 
throughout the marginal cells. SV Scala vestibuli. SM Scala Media. ST Scala tympani. 
BM Basilar membrane. LW lateral wall. 
 
Spiral ligament 
NKCC1 was found in multiple fibrocytes of the spiral ligament (Fig. 19), most 
likely within type II18 and/or IV38 as these are the closest to the root cell projections2.  
NKCC1 expression extended laterally through fibrocytes of the spiral ligament, but not 
the root cells.  The expression level was less intense in the fibrocytes closer to the stria 
vascularis (types I, IV, and V18,68,2).  NKCC1 was not found in root cells of the spiral 
ligament and consequently was not co-expressed with NPR-A in the spiral ligament. 
NPR-A and NKCC1 were intermittently co-localized in some areas of the 
cochlea, but were separate in other areas (Fig. 20).  A sporadic pattern of co-localization 
was observed in the interdental cells of the spiral limbus and the marginal cells of the 
stria vascularis.  No intercellular localization was noted in the basal cells of the stria 
vascularis or the cells of the spiral ligament.  Furthermore, fibrocytes in the spiral limbus 
did not exhibit co-localization, but did express both NPR-A and NKCC1.  NPR-A and 
NKCC1 did not co-localize in the spiral ganglion, as NKCC1 expression was not 
observed in nerve tissue. 
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Figure 19: NPR-A and NKCC1 did not co-localize in the spiral ligament. 
25x images of the spiral ligament from CBA 596. A. Control section with no primary 
antibodies. B. Experimental image with anti-NPR-A primary antibody (red). C. 
Experimental image with anti-NKCC1 (green). D. Merged image showing double label 
of NPR-A (red) and NKCC1 (green) with Hoechst reagent (blue). Asterisk indicates root 
cell bodies in the outer sulcus with lateral projections (arrows) or where they would 
appear (C). Note the lack of overlap between the red NPR-A label of the root cells and 
the green NKCC1 label of the surrounding fibrocytes. StV stria vascularis. SLg spiral 
ligament. LW lateral wall. 
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Figure 20: Summary diagram of NPR-A and NKCC1 noting areas of co-localization. 
Summary diagram of the expression of NPR-A and NKCC1 in the cochlea showing 
specific regions positive for NPR-A and NKCC1 labeling. Co-localization was the most 
intense in the interdental cells of the spiral limbus, although still not continuous.  Co-
localization was also seen in the marginal cells of the stria vascularis. NKCC1 (in 
fibrocytes) and NPR-A (in root cells) were both expressed in the spiral ligament, but in 
different cells. NPR-A expression as also seen in the basal cells of the stria vascularis and 
spiral ganglion cells, where NKCC1 was not found. Some label of both proteins was also 
observed in the tectorial membrane. For simplicity, areas with co-localization are 
depicted as solid yellow, however the overlap was intermittent and did not penetrate the 
entire cell body when observed. 
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Discussion 
 NPR-A is acting in two major systems of the cochlea.  Firstly, NPR-A is in a 
position to play a critical regulatory role in the movement of potassium ions through the 
medial and lateral K+ recycling systems, based on the labeling pattern of NPR-A in the 
spiral limbus (Fig. 14 and Fig. 17), the root cells of the spiral ligament (Fig. 14 and Fig. 
19), and the basal and marginal cells of the stria vascularis (Fig. 14 and Fig. 15). 
Secondly, the expression of NPR-A in the cell bodies and central/peripheral processes of 
the spiral ganglion neurons (Fig. 12 and Fig. 14) indicates that NPR-A may also play a 
role in neurotransmission within the cochlea.  Before discussing the functional 
implications of these findings, the argument for specificity of label will be presented. 
Specificity	  of	  Label	  
 The results from control experiments indicated the NPR-A antibodies were 
performing as expected because 1) the primary antibodies were specific to the antigens 
(as designed), 2) the secondary antibodies were specific to the primary antibodies, and 3) 
the positive and negative controls supported the predicted expression patterns in those 
tissues. 
1) Primary antibodies were specific to the antigens 
 The two antibodies that were used to localize NPR-A targeted different regions of 
the protein.  The N-terminal antibody (Abcam) and the C-terminal antibody (Potter) 
showed homologous expression patterns of NPR-A in 4 distinct regions of the cochlea 
with slight variations in expression intensity.  Reported data from western blot analyses 
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was used to assess the quality and specificity of the antibodies, and BLAST searches 
were performed to determine other potential targets for the antibodies.  Also, the staining 
in the tectorial membrane and organ of Corti will be addressed (label in non-specific 
tissues).  
Using western blot analysis (other labs), the N-terminal (Abcam)69 and the C-
terminal (Potter)70 antibodies each only yielded one band, suggesting that each antibody 
only binds to one protein.  This information provides evidence that the observed 
expression pattern in our immunohistochemistry results can be attributed to the NPR-A 
protein (and not non-specific binding of the antibodies).  Experiments using both the N-
terminal69,71–74 and C-terminal44,56,70 antibodies have been reported, indicating they have 
been accepted as successful targets for their antigens. 
Further support that the primary antibodies were specific to their targets was 
obtained from BLAST data using the protein databank from the National Center for 
Biotechnology Information (ncbi.nlm.nih.gov).  The search for the antigen targets of the 
two NPR-A antibodies did not yield the same result i.e. the nearest overlapping protein 
sequence was not the same for each antibody, making it unlikely that the antibodies were 
binding to a protein of similar sequence to NPR-A.  Iodotyrosine deiodinase had a 45% 
identity to the NPR-A antigen.  Native to the thyroid gland, Iodotyrosine deiodinase (Iyd) 
is an enzyme that catalyzes deiodination of halogenated byproducts of thyroid hormone 
production critical to iodide retrieval75,76, and has not been reported in the inner ear.  For 
the C-terminal antibody (Potter), the closest protein sequence was for asparaginyl 
endopeptidase (AEP), a lysosomal cysteine protease active on asparagine residues near 
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C-terminal regions of proteins77,78, with a 69% protein identity.  Important to lysosomal 
degradation and toll-like receptor maturation, AEP is native to the kidney and spleen and 
may play a role in red blood cell maturation77.  Because the BLASTs against the two 
NPR-A antibodies did not yield the same protein, nor were those proteins (Iyd and AEP) 
native to the cochlea, it is, therefore, unlikely that the primary antibodies were not 
binding to other antigens with similar protein sequences. 
The N-terminal and C-terminal antibodies had similar expression patterns in the 
cochlea with two distinct exceptions: intensity of labeling in the stria vascularis and 
expression pattern of labeled cells in the spiral limbus.  The C-terminal target had a 
lighter intensity of label in both the marginal and basal cells of the stria vascularis (Fig. 
14d), but showed identical cellular localization, supporting the conclusion that NPR-A 
was expressed in these cells of the stria vascularis.  The other major difference between 
the antibodies was the staining in the cells of the spiral limbus, where the N-terminal 
target was specific only to interdental cells, but the C-terminal target was found in limbal 
fibrocytes (Fig. 14f). 
One explanation for the differences in staining may be the density of the tissue or 
availability of the antigen, as the C-terminal is internal and may be more difficult to 
access.  A second explanation for both the variations in labeling intensity and the 
differential expression in limbal fibrocytes is phosphorylation events at the time of tissue 
collection.  As previously mentioned, the C-terminal of the protein is internal to the cell 
and is near the guanylyl cyclase domain45,79.  Phosphorylation or dephosphorylation may 
alter the availability of the C-terminal target.  A third explanation for the differences 
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between the two NPR-A antibodies in the spiral limbus may be glycosylation events in 
the N-terminal region of the receptor protein.  Glycosylation of the N-terminal region 
(external to the cell, where ANP binds) may affect the affinity of ANP for its receptor80, 
suggesting that there may be differing availability of the N-terminal region (the Abcam 
antibody target) depending on the glycosylation events at the time of tissue collection. 
Although unexpected, the expression of NPR-A in the limbal fibrocytes does not 
change the conclusion that NPR-A is crucial to potassium recycling, as the fibrocytes of 
the spiral limbus could be a transition point for K+ from the gap-junction network (see 
“Role of NPR-A in K+ recycling” below) to a less differentiated connective tissue gap-
junction network in the inner sulcus.  This conclusion is further supported by the fact that 
using the C-terminal (Potter) antibody, we observed NPR-A more heavily on the medial 
portion of the spiral limbus. 
 Both NPR-A antibodies and NKCC1 labeled the tectorial membrane, while the 
Kir4.1 antibody labeled only lightly or not at all in this tissue. The tectorial membrane is 
a connective tissue secreted by the interdental cells of the spiral limbus11.  It is composed 
of three collagen types and three glycoproteins known as tectorins81,82.  There are several 
potential explanations for the unexpected labeling of the tectorial membrane by the NPR-
A and NKCC1 antibodies.  First, these two proteins could secreted by the interdental cells 
of the spiral limbus as the tectorial membrane is being synthesized.  This is purely 
speculative, however, as there are no reports of transmembrane receptors/channels that 
can be excreted into the extracellular matrices. 
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A second, more likely explanation for the observed staining in the tectorial 
membrane is that the secondary antibodies became “stuck” to the tissue as it is naturally 
adhesive.  There was no label in the control sections (no primary antibody) (Fig. 18a), 
suggesting that the primary antibody sites did not stick in the tectorial membrane.  
Additionally, there was no labeling of the tectorial membrane observed with the Kir4.1 
antibody, which used the same secondary as the NKCC1 antibody. 
 Another plausible explanation for labeling in the tectorial membrane may be the 
blocking agents that were used.  NPR-A and NKCC1 both received 1% milk blocking 
solutions in PB or PBS, while Kir4.1 received amore specific serum blocking solution 
(Table 4).  It is possible the staining in the tectorial membrane was due to the non-
specific binding of the NPR-A and NKCC1 secondary antibodies to the milk blocking 
agent.  This possibility would account for the lack of label of Kir4.1 in the tectorial 
membrane, but does not explain why the secondary antibody bound non-specifically to 
the tectorial membrane and not other tissues. 
Finally, staining in the tectorial membrane may simply be due to the condition of 
the tissue on the section.  During cryosectioning, it was common for tissues like the 
tectorial membrane and cells in the organ of Corti to fold, creating grooves in the tissue 
where antibodies could wedge.  If this happened, then they may not wash out during 
labeling.  Folding of the tissues was a common problem, as collapsed cells in the organ of 
Corti, pieces of the cerebellum, and the vestibular system also rarely, but occasionally 
exhibited un-specific label (Fig. 18b). 
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2) Secondary antibodies were specific to the primary antibodies 
Several experiments were performed to provide more evidence that the observed 
cochlear labeling was specific to the target proteins.  To confirm the observed staining 
was due to the presence of NPR-A and NKCC1, this study was designed to a) account for 
background staining, b) use multiple secondary antibody tags, and c) analyze control 
sections without primary antibodies. 
One problem with immunohistochemistry is that there can be too much 
background staining to observe the specific expression patterns of the antibody.  This can 
be from primary antibodies, secondary antibodies, or both.  To avoid this, multiple 
blocking agents were tested to determine which block provided the least amount of 
background.  Ultimately, the specific blocking solutions were chosen for each antibody 
based on the level of background expression of antibody dilutions.  For example, the N-
terminal anti-NPR-A antibody (Abcam) had the least background with a milk/pb block at 
a 1:50 dilution (Table 4). 
A second problem can be non-specific binding of the secondary antibody.  To 
ensure that the observed staining pattern was specific to target protein (and not due to 
non-specific binding of the secondary antibody), multiple preliminary experiments were 
performed with secondary antibodies of different hosts and fluorescent ranges (some data 
not shown).  NPR-A was labeled with the Alexa 568 (red) goat anti-rabbit secondary 
antibody (as observed in the above figures).  In separate experiments, NPR-A was labeled 
using an Alexa 488 (green) donkey anti-rabbit secondary antibody (data not shown).  
These two secondary antibody labels showed similar expression levels of the NPR-A 
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protein for the same primary antibody.  Based on these preliminary experiments, it is 
likely that the secondary antibodies were specifically binding to the primary antibodies as 
designed. 
Control sections were run with each experiment using the same protocol, but 
receiving the blocking agent instead of the primary antibody during the labeling step in 
order to be sure there was no non-specific binding of the secondary antibodies.  Any 
binding observed in the control sections would be non-specific binding of the secondary 
antibody.  Little to no staining was observed on the control sections, further confirming 
that the secondary antibodies were specifically binding to the primary antibodies. 
During imaging, similar settings were used on the confocal microscope (Table 5) 
to ensure comparability between the images and experiments.  These settings were also 
conserved between experimental and control (no primary antibody) sections to ensure 
that background levels were evaluated appropriately.  This provided information that the 
variances in staining intensities observed was not due to different settings upon data 
collection. 
3) Staining Consistent with Previous Reports 
In addition to theoretical considerations of binding specificity, the antibody 
experiments were performed on positive kidney control and negative muscle control 
tissues where the expression of NPR-A and NKCC1 were already known.  These two 
positive and negative control experiments provide confidence that specific labeling of the 
NPR-A and NKCC1 protein was observed when expected, and not in tissue that would 
not express these proteins. 
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3a) Positive control: staining in the kidney tissue 
The kidney was used as a positive control for both NPR-A and NKCC1 as both 
proteins have both been reported in the kidney using multiple techniques64,67,83–85.  Using 
immunohistochemistry, NPR-A has been found in the collecting duct (both medullary64 
and cortical65) and in both the renal glomeruli and capillaries63,84 as observed in this study 
(Fig. 6).  These studies also observed light labeling in the medulla, which can be 
attributed to either the loop of Henle or the medullary collecting duct64,84.  It should be 
noted that there was considerable background labeling of NPR-A in the kidney.  While 
this background label was brighter than the corresponding label in the cochlea, there was 
more intense specific label in the areas that have been reported to contain NPR-A (Fig. 6 
arrows). 
NKCC1 has been localized to the glomeruli of the cortex, and the collecting duct 
in both the cortex and medulla67,85 as was observed in these experiments.  Overall the 
observed results were consistent with the reported locations, supporting the position that 
the positive staining observed in the cochlea was specific to the NPR-A and NKCC1 
proteins and not due to background staining.  The expression patterns of NPR-A and 
NKCC1 in the kidney indicate the antibodies used in this study were working correctly, 
as they labeled positive control cells reported to express these proteins, and did not label 
negative control cells that do not express these proteins. 
3b) Negative control: lack of stain in the muscle tissue 
In addition, negative control experiments were performed using the quadriceps 
muscle (Fig. 7).  NPR-A66 and NKCC167 have not been reported in skeletal muscle, and 
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therefore should not be expressed in this tissue.  While in the muscle there was a slight 
color change between the control image and the experimental one, this was most likely 
due to the natural fluorescence of the tissue or slight background labeling, and less to do 
with potential positive labeling of the proteins. 
3c) LCM and qRTPCR support immunohistochemical results 
 Using laser capture microdissection to isolate specific cells in concert with qRT-
PCR to amplify the NPR-A mRNA and the time of collection should have yielded results 
about the relative expression levels of NPR-A in specific cells of the cochlea.  Ideally, 
using LCM would provide specific cell isolates from different cochlear regions and 
thereby provide a basis to quantitatively compare NPR-A mRNA expression between cell 
populations.  Although this experiment was designed as a second confirmation of NPR-A 
expression in different cochlear regions (in addition to the immunohistochemistry 
experiments), these data were not entirely successful due to the poor RNA quality and 
difficulty of performing laser capture microdissection on the cochlea. 
While the cochlear LCM extracts did not yield information, important results 
were captured from the kidney LCM samples and the homogenate tissue samples.  These 
studies were able to confirm the presence of NPR-A mRNA in both kidney and cochlear 
homogenate samples, concluding that the primers were binding to NPR-A and providing 
evidence that NPR-A was produced in these tissues.  Quantitative PCR demonstrated the 
presence of NPR-A in the medulla.  Usable data were not yielded from the cortex LCM 
samples, most likely due to the RNA quality and not the fact that NPR-A was not actually 
present in the kidney cortex.  This conclusion is plausible because of the other controls 
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performed in these experiments to confirm the NPR-A label, as well as support from the 
literature for NPR-A expression in both the renal medulla and cortex63,65,84. 
While the information about NPR-A expression in these tissues is not novel, the 
fact that the cochlea, a significantly smaller tissue than the kidney, expressed comparable 
amounts of NPR-A mRNA as the kidney is significant (Fig. 9).  It has long been accepted 
the NPR-A is a major regulator of the cardiovascular and renal systems, but the effects of 
NPs on hearing are rarely discussed.  Using the qPCR data collected in these studies, 
NPR-A is likely to have a very significant role in the cochlea due to the expression levels 
of NPR-A reported.  Furthermore, extrapolating from the two LCM samples that showed 
compatible expression levels to the other tissues, cochlear cells could yield successful 
mRNA qualitatively similar to the NPR-A expression levels shown in the kidney LCM 
samples (Fig. 9).  The kidney LCM results provide evidence that the NPR-A 
immunohistochemical labeling is specific to the antigen, and suggests that similar LCM 
results will be observed in the cochlea. 
NPR-­‐A	  Expression	  in	  Cochlear	  Neurons	  
NPR-A was detected throughout the entirety of type I spiral ganglion neurons 
including the central and peripheral processes (Fig. 11 and Fig. 12c).  Kir4.1 expression 
was observed in the Schwann cells of the spiral ganglion, but not the cell bodies of the 
neurons (data not shown).  Co-localization between NPR-A and Kir4.1 was not observed 
in these cells, suggesting NPR-A was found only in the neurons themselves.  There is no 
definitive molecular marker to distinguish between type I and type II spiral ganglion 
cells, but there are several lines of evidence that NPR-A was expressed in only type I 
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spiral ganglion cells for three main reasons.  Firstly, the cell bodies that stain with NPR-
A were located throughout the spiral ganglion and not just on the periphery.  Secondly, 
the morphology of the cell bodies coincided with descriptions of Type I spiral ganglion 
cells in that they were large, spherical bodies.  Lastly, NPR-A expression was clearly in 
the peripheral processes of the spiral ganglion that communicate with inner hair cells 
(Type I) (Fig. 11), but not within the basilar membrane or underneath the outer hair cells, 
which would indicate expression in Type II neurons.  Taken together, these results 
support attribution of NPR-A to type I spiral ganglion neurons, but not type II neurons.  
This novel finding may indicate NPR-A could be used as a molecular marker to 
distinguish between spiral ganglion neurons.  Further experiments need to be performed 
in order to explicitly confirm NPR-A expression was localized to only type I spiral 
ganglion neurons. 
While the evidence indicates that NPR-A was expressed in spiral ganglion cells, 
these cells are not components of the K+ recycling system and therefore the presented 
hypothesis would not have predicted the expression of NPR-A in that region.  
Nevertheless, there are several potential functions for NPR-A in spiral ganglion neurons.   
There is recent evidence that NPs may function in a number of roles in the central 
nervous system including neural development, neurotransmitter uptake and release, 
regulation of synaptic function, and/or neuroprotection86.  While NPR-A may not be in 
the spiral ganglion because of the K+ gateway, it may have functional roles other than ion 
transport in the cochlea.  NPR-A has been localized to the trigeminal nerve, where 
activation by BNP may play a role in nociception and as a delayed regulator to sensory 
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excitability72.  These authors suggested that BNP/NPR-A secondary messenger activation 
might have antinociceptive functions in the trigeminal nerve.  NPR-A has also been 
localized to the dorsal root ganglion.  Activation of NPR-A by BNP may play a role in 
scratch response and itch detection74. 
In the brain, NPR-A mRNA expression has been localized to the subfornical 
organ and habenula of the central nervous system86.  The subfornical organ plays a role in 
osmoregulation87 as well as regulation of the cardiovascular system87,88; NPs are known 
regulators of these two systems.  The habenula has functional roles in pain processing, 
sleep-wake cycles, mood and depression, nutrition, stress response, and learning89.  
Although the presence of NPR-A in the spiral ganglion was not anticipated, NPs and in 
turn their receptors have been localized to the nervous system.  Therefore, NPR-A may 
have a functional role in signal processing of spiral ganglion neurons. 
NPR-­‐A	  expression	  in	  gateways	  for	  K+	  recycling	  
 
 NPR-A was found in areas of transition in the K+ recycling systems i.e. regions 
where K+ must flow between different cell types or exit into the endolymph.  As 
previously described, the movement of potassium ions in the cochlea is highly regulated 
and critical to hearing.  K+ cycles through the cochlea in two major directions: 1) in the 
outer sulcus system from the outer hair cells laterally through the spiral ligament and out 
of the stria vascularis into the scala media (Figs. 1 and 21 blue)2 and 2) in the inner sulcus 
system from the inner hair cells medially through the spiral limbus and out of the 
interdental cells into the scala media (Figs. 1 and 21 purple)11.  Based on the expression 
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of NPR-A in the spiral limbus, spiral ligament, and the stria vascularis, NPR-A was 
clearly localized to cells that are vital to the transition of K+ these two systems. 
 
 
Figure 21: NPR-A and NKCC1 Expression in gateways for K+ transition in the 
inner and outer recycling systems. 
NPR-A is expressed in cells key for K+ movement either into or out of different cellular 
networks, or from a cell into the endolymph. This expression pattern implicates NPR-A 
as a key regulator for K+ transition from the different recycling networks. The numbers 
indicate the gateway for K+ movement with the inner sulcus system has 5 gateway points 
and the outer sulcus system has 6 gateways. There is no number between the basolateral 
and apical marginal cell boxes as they are within the same cell where K+ can freely 
diffuse. 
1) NPR-A expression in the outer sulcus K+ recycling system 
 There are six gateways where the movement of K+ can be regulated in the outer 
sulcus system: 1) into the apical pole of the outer hair cells via the mechanotransduction 
channels, 2) between the outer hair cell basal pole and the epithelial gap-junction network 
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of the organ of Corti, 3) between the root cells in the outer sulcus and the fibrocytes of 
the connective tissue gap-junction network in the spiral ligament, 4) between the 
connective tissue gap-junction network and the basal cells of the stria vascularis, 5) from 
the intrastrial space into the basolateral pole of the marginal cells, and 6) from the 
luminal surface of the marginal cells of the stria vascularis into the endolymph.  Within 
the outer sulcus system, NPR-A was expressed in four of these six transition points (Fig. 
21 blue panel).  This evidence suggests a critical regulatory role for ANP in the 
movement of K+ through transitioning systems/cell types. 
 NPR-A was not expressed in the outer hair cells or any of the supporting cells of 
the organ of Corti.  Therefore, it is unlikely NPR-A plays a regulatory role in K+ 
movement through the first two gateways of the outer sulcus recycling system (1- into the 
apical pole of the outer hair cells and 2- exit from the basolateral pole of the hair cells 
into the epithelial gap-junction network).  In these areas, K+ travels out of the basolateral 
pole of the outer hair cells via Kv7.435,90 and into Dieter’s cells via KCC3 and KCC4 and 
to some degree Kir4.12,36.  There are no reports that NPR-A activates any of these 
transporters or channels in other tissues. 
NPR-A expression in the root cell gateway 
NPR-A was heavily expressed in the third gateway for K+ transition in the outer 
sulcus K+ recycling system: the root cells of the spiral ligament (Fig. 19).  Functionally, 
root cells are the part of the epithelial gap-junction network2,91 and represent the 
transition point where K+ ions must move out of the epithelial gap-junction network into 
the connective tissue gap-junction network2.  NKCC1 was also expressed in the spiral 
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ligament but specifically not in the root cells and therefore, the downstream effector for 
NPR-A in the root cells is unknown. 
NPR-A expression in the basal cell gateway 
Once K+ transitions into the connective tissue gap-junction network (third 
gateway Fig. 21 blue side), it can flow between fibrocytes of the spiral ligament and into 
the stria vascularis (fourth gateway Fig. 21 blue side).  NPR-A was heavily expressed in 
the basal portion of the basal cells of the stria vascularis in the region where K+ flows 
from ligamental fibrocytes into the basal cells via gap-junctions.  There are conflicting 
opinions of which fibrocytes form gap-junctions with the basal cells.  Spicer and Schulte 
(1996) propose type Ia and Ib fibrocytes connect with the basal cells18, while Zdebik et 
al. (2009) claim it is types IV and V3. 
Although basal cells are connected to the fibrocytes via gap-junctions3,20,26, the 
nature of the K+ gradient would suggest it would be optimal to have regulation of the 
gap-junctions to ensure K+ movement into the high voltage/low K+ concentration internal 
environment in the intrastrial space.  Although there are no reports of cGMP regulation of 
gap-junctions, there is evidence that the assembly of and communication through gap-
junctions can be affected by second messengers like cAMP92,93.  Furthermore, cAMP 
reduces the permeability of Connexin-2694, a major component of most cochlear gap-
junctions95, likely acting to control the flow of K+ into the basal cells.  Although this 
gateway for K+ exhibits less physical segregation than in root cells [i.e. there are gap-
junctions rather than separated cells between the two systems], NPR-A may still act as a 
regulator for K+ by modifying traffic through the gap-junctions, and thereby controlling 
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K+ influx from the connective tissue gap-junction to the stria vascularis.  Therefore, the 
natriuretic peptide cascade triggered by NPR-A activation may also influence passive K+ 
transport through pores and not just active K+ transport. 
NPR-A expression in the marginal cell gateway 
Marginal cells account for the final two gateways for K+ recycling through the 
outer sulcus system.  Potassium ions travel into the marginal cells basolaterally from the 
intrastrial space (gateway 5).  K+ is then excreted into the endolymph along the apical 
portion of the marginal cells via KCNQ1 (gateway 6) (Fig. 21).  NPR-A was expressed 
throughout the entire marginal cell (Fig. 18), implying that the secondary messenger 
cascade may stimulate transporters for both K+ influx and efflux within the marginal 
cells. 
The intrastrial space lateral to the marginal cells has an extremely high voltage 
(100 mV), but low K+ concentration (Fig. 2).  K+ is moved from the basal cells to the 
intermediate cells via gap-junctions (Connexins 26 and 30)3.  Once in the intermediate 
cells, Kir4.1 leaks K+ into the intrastrial space creating the endocochlear potential.  The 
marginal cells take up K+ basolaterally through several transporters including NKCC1 
and Na+/K+ ATPase23,26.  K+ moves out of the stria vascularis on the luminal surface of 
the marginal cells26, thus completing the K+ recycling pathway of the outer sulcus 
system. 
NPR-A mRNA has been found in the stria vascularis using whole strial cell 
isolation and PCR52.  However, this work did not distinguish among the different cell 
types composing the stria vascularis.  Qiao et al. showed NPR-A and ANP expression via 
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RTPCR in cultured marginal cells isolated from the stria vascularis 53.  Consistent with 
these findings, in this study, both the N-terminal and C-terminal anti-NPR-A antibodies 
localized NPR-A expression to the marginal cells. 
Co-localization between NPR-A and Kir4.1 was not observed (Fig. 15), 
suggesting any NPR-A label in the intermediate layer of the StV was due to marginal cell 
projections that penetrate the layers of the StV to the basal cell layer (Fig. 2).  Some of 
this expression could be due to the basal cell projections, however they do not penetrate 
the intermediate cell layer as deeply as marginal cells20.  Furthermore, while Kir4.1 is 
commonly used as a marker for intermediate cells96, it is possible co-localization was not 
observed as the label may not penetrate the entire cell body.  However, the lack of any 
co-localization between NPR-A and Kir4.1 indicates NPR-A was likely only expressed in 
the marginal and basal cells of the stria vascularis. 
NPR-A was expressed throughout the body of the marginal cells and 
intermittently co-expressed with NKCC1, which was local only to the basolateral 
plasmalemma (Figs. 18 and 20).  Because NPR-A was expressed throughout the whole 
marginal cell, and not just one pole, it could regulate both K+ influx basolaterally via 
NKCC1 and K+ efflux apically through an unknown effector.  This is an important 
finding in that movement of K+ is critical to maintain proper hearing function.  Research 
in the cardiovascular system and ovary has shown there is a functional phenotypic link 
between gene mutations in KCNQ1 and NPPA (natriuretic peptide precursor A), a gene 
that codes for ANP (the ligand of NPR-A).  Using a registry of patients with familial 
atrial fibrillation, 231 people expressed both of the mutations and exhibited symptoms of 
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early onset lone atrial fibrillation.  These results suggest two different mutations in the 
4q25 chromosomal loci lead to the same phenotypic condition97,98.  This information may 
imply there is also a functional connection between KNCQ1 and NPs in the inner ear, 
which reflects many of the same protein relationships the cardiovascular and renal 
systems express in regards to NPs and their effectors. 
2) NPR-A expression in the inner sulcus K+ recycling system 
There are five gateways for K+ transition in the inner sulcus system: 1) into the 
inner hair cells from the endolymph via the mechanotransducer channel, 2) out of the 
inner hair cells and into the medial epithelial gap-junction network, 3) through the 
epithelial gap-junction network and into the limbal fibrocytes, 4) from the limbal 
fibrocytes into the interdental cells, and 5) out of the interdental cells to the endolymph.  
While the movement of K+ through the outer sulcus system has been well documented, 
the movement through the inner sulcus recycling system is much less understood.  In the 
inner sulcus recycling system, there are fewer gateways and less functional segregation 
between cells.  Anatomically, there is a less clear transition between inner sulcus cells 
and limbal fibrocytes.  This medial system is more analogous to the flow of K+ in the 
vestibular system, where there is less development of specific cell types and segregation 
of networks11. 
In a similar manner to the outer sulcus recycling system, NPR-A was not 
expressed in the first two gateways of the inner sulcus recycling system (1- influx 
through the MET channel into the apical pole of the inner hair cells and 2- efflux from 
the inner hair cells in to the underlying supporting epithelial gap-junction network).  As 
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in the outer hair cells, K+ exits the inner hair cells via multiple K+ channels and to a lesser 
degree, Kir7.490, and is then taken up by inner phalangeal cells of the organ of Corti via 
KCC33,36.  Inner phalangeal cells do not express KCC43,36. 
NPR-A Expression in the limbal fibrocytes 
Using the C-terminal antibody (Abcam), NPR-A was identified in the limbal 
fibrocyte network of the spiral limbus (third gateway) (Fig. 14), where K+ exits the 
epithelial gap-junction system and enters the spiral limbal fibrocytes.  There is little 
information about what makes a cell a limbal fibrocyte versus an inner sulcus cell, so 
there may be some overlap between these regions11.  Functionally, this area is likely 
analogous to the root cell gateway in the outer sulcus recycling system, although it is 
unclear whether this pathway delineated as the pathway via the root cells.   Using the C-
terminal antibody (Potter), NPR-A was expressed along the inner sulcus and therefore 
may act to influence an effector in this region.  Furthermore, NPR-A may act medially 
through fibrocytes on the other side of the spiral limbus and consequently regulate flow 
in this region.  Even though the inner sulcus recycling system is not as distinguished as 
the outer sulcus system, NPR-A was still positioned in areas critical for K+ transition 
between networks or cells. 
NPR-A Expression in the interdental cell gateways 
NPR-A was localized to the fourth gateways involving the interdental cells in a 
manner similar to the marginal cells of the outer sulcus recycling system.  Based on the 
current anatomical knowledge about this tissue, it is unclear if there are two separate 
gateways (analogous to the stria vascularis in the outer sulcus system), or if there is only 
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one transition point.  Interdental cells act to sequester compounds from the limbal 
fibrocytes and export them into the endolymph12,18.  Therefore, activation of NPR-A in 
these cells may cause stimulation of transporters to move K+ into the cell along the 
basolateral pole and/or out of the cell apically via KCNQ1 (similar to marginal cells in 
the stria vascularis). 
Comparison with previous localization studies 
 Reports describing the presence of NPR-A in the cochlea provide inconsistent 
descriptions regarding the precise localization to specific cell types, which necessitated 
the design of this study.  Most previous reports agree that NPR-A is localized to the 
lateral wall, but there are differing opinions of which cells specifically express NPR-A.  
NPR-A was first found in the cochlea in studies that used audioradiography, which 
showed that it was present in the stria vascularis, but not the organ of Corti42,51,99.  Using 
in situ hybridization, NPR-A was found in the spiral ligament and the Schwann cells of 
the cochlear nerve, but not the stria vascularis41,54.  The results presented in this 
manuscript support the audioradiography and in situ hybridization data that NPR-A was 
present in the StV and spiral ligament.  By contrast, in this study NPR-A was localized to 
the spiral ganglion neurons and not the Schwann cells (Fig. 11 and Fig. 16).  PCR of 
strial mRNA showed expression of NPR-A in the stria vascularis, but did not provide 
information about expression within individual cell types52.  Furthermore, NPR-A mRNA 
has been found in cultured marginal cells, but this study was not able to provide detailed 
information about positional expression in the intact organ53.  The current experiments 
using immunohistochemistry and qRT-PCR provide novel information not only about the 
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specific tissue expression of NPR-A, but also its morphological relationship to two other 
proteins expressed in the cochlea (NKCC1 and Kir4.1).  This work provides critical 
information about the potential role of NPR-A in K+ recycling and neurotransmission, 
and further supports the hypothesis that natriuretic peptides play important roles in 
hearing. 
Natriuretic	  Peptide	  System	  in	  the	  Cochlea	  
The combination of NPR-A expression in the interdental cells of the spiral 
limbus, the root cells of the spiral ligament, and the basal and marginal cells of the stria 
vascularis supports the hypothesis that NPR-A is expressed in areas critical for K+ 
movement.  More specifically, these five cell types [root cells, basal cells, marginal cells, 
limbal fibrocytes, and interdental cells] are all in gateway areas where K+ is transitioning 
from either a tissue type/specific network or out of a tissue and into the endolymph.  This 
novel information addresses questions with respect to the role(s) NPR-A is playing within 
the cochlea.  Binding of atrial natriuretic peptide presumably leads to activation of NPR-
A in these areas, jumpstarting the recycling of K+ and contributing to the maintenance of 
hearing thresholds.  These interpretations are supported by evidence that NPR-A 
knockout mice exhibit progressive high-frequency hearing loss50, which cannot be 
reversed by infusion of ANP49.  Data were also obtained in this study that provide 
information regarding the mechanism underlying the actions of ANP in the cochlea.  Two 
aspects of the ANP/NPR-A pathway will be discussed below: 1) ANP/NPR-A interaction 
and 2) potential downstream effectors for NPR-A. 
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1) ANP/NPR-A Interaction in the Cochlea 
The first step in the ANP pathway is the binding of ANP to NPR-A causing the 
generation of cGMP from GTP.  ANP can be delivered systemically to the inner ear via 
the blood vessels of the stria vascularis49, which represents signaling in an endocrine 
fashion.  With ANP delivery specific only to cells near the blood supply, it could be 
hypothesized that NPR-A expression would be localized in and around only cells where 
ANP is systemically delivered (strial vascular cells).  However, this hypothesis was not 
reflected in the results of this experiment, as NPR-A was expressed in 6 cells types in 4 
different regions of the cochlea, and not just in cells of the blood vessels of the stria 
vascularis.  Although the mechanism for systemic ANP activation of NPR-A in the 
cochlea remains undetermined, ANP could also act in a paracrine or autocrine fashion.  
There is evidence that ANP can be produced in the cochlea, as the activating hormone, 
corin, has been localized within the stria vascularis, organ of Corti, and modiolus of the 
inner ear using RT-PCR100.  If ANP is produced in the cochlea, it is conceivable that 
NPR-A would be expressed in tissues not directly in diffusion range of the blood supply 
from the stria vascularis.  This hypothesis was reflected in the results of this experiment, 
with NPR-A expression in six cell types that are physically separated from cochlear 
blood vessels. 
Looking at the pathway of activation, ANP (or BNP) binds to NPR-A triggering 
events in the kinase homology domain (Fig. 4) [dephosphorylation45,66, 
phosphorylation62,83,101, or both].  This action causes a conformational change in the 
internal pole of the receptor, dimerizing the guanylyl cyclase domain leading to the 
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generation of cGMP66.  Natriuretic peptides affect this system, as systemic delivery of 
ANP causes a marked increase in the production of cGMP in the cochlea102.  This second 
messenger system then acts to stimulate other molecular activators such as PKG.  
Ultimately, the activation of NPR-A by ANP leads to a change in hearing, presumably 
due to effectors in the proposed ANP pathway to change the endocochlear potential. 
2) Potential Effectors for NPR-A in the Cochlea 
Once NPR-A has activated PKG, it can theoretically influence the activity of a 
number of different channels and transporters causing the observed change in hearing 
thresholds.  While the beginning of the pathway has been determined by the work on 
natriuretic peptides in our lab49,50, other labs41,42,51,53,99, and other systems40,79,103, little 
work is being done to connect the natriuretic peptide system to the downstream effectors 
that could result in changes to auditory thresholds.  The results of this study provide a 
direct link to what is known about cochlear function and what is known about the role of 
natriuretic peptides in fluid and ion regulation. 
 Looking at the relationship between NPR-A and NKCC1, it was clearly a more 
complicated answer than, “yes NKCC1 is the only effector for NPR-A” or “NPR-A is the 
only regulator of NKCC1”.  In the six cell types that showed NPR-A expression, a) two 
cell types may intermittently use NKCC1 as an effector (marginal cells and interdental 
cells) as some co-localization was observed, and b) four cell types did not show co-
expression of NPR-A and NKCC1 (basal cells, root cells, limbal fibrocytes, and spiral 
ganglion did not express NKCC1) and therefore must use another effector.  There is a 
possibility that cGMP could diffuse between cells expressing NPR-A and then activate 
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proteins in adjacent cells containing NKCC1 meaning there is a possibility NKCC1 could 
still be an effector in the ANP pathway when co-localization is not observed.  It should 
also be noted that the discussions below are based on the observed co-localization 
patterns alone and not on any functional studies.   
2a) Cells that might use NKCC1 as an effector 
NPR-A in marginal and interdental cells occasionally co-localized with NKCC1, 
implicating this transporter as an effector activated by ANP.  Marginal cells are the major 
output source for K+ from the intrastrial space where intermediate cells generate the 
endocochlear potential.  A critical channel is KCNQ1, which is present along the luminal 
surface of the marginal cells90,104,105.  Based on the degree of co-localization between 
NPR-A and NKCC1 in the interdental and marginal cells was intermittent, NKCC1 may 
not be the only protein important to K+ movement that is stimulated by the activation of 
NPR-A in these areas. 
Looking specifically at marginal cells, it is interesting to consider the expression 
of NPR-A appears throughout the entire cell body and not just one pole.  In turn, it can be 
inferred that NPR-A may be important in activating proteins responsible for both K+ 
influx in one pole and other proteins responsible for K+ efflux on another pole.  In the 
marginal cells, intake is attributed to Na+/K+ ATPase and NKCC1 basolaterally, and 
export to the endolymph is from KCNQ1 expressed along the luminal surface104.  
Furthermore, for both cell types NKCC1 was clearly not the only effector (as co-
localization was sporadic), and therefore it could also stimulate export proteins for K+ 
efflux into the endolymph, such as KCNQ1.  While the physical relationship of NPR-A to 
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KCNQ1 is not known, ANP has been documented to influence the expression level of 
KCNQ1 in cancer cells106.  In interdental cells, it is unclear if a similar situation occurs 
with the distribution of transporters (NKCC1 for K+ influx and another transporter 
activated for K+ export).   
2b) Cells that do not use NKCC1 as an effector 
 NKCC1 expression was not observed in the spiral ganglion, indicating these cells 
have to be utilizing another effector protein in the ANP pathway.  NPR-A expression in 
neuronal tissue is a relatively new observation72,74,86, and is therefore still being 
determined.  In both strial basal cells and the root cells of the spiral ligament, NKCC1 
was localized to the region, but did not co-localize with the cells expressing NPR-A.  
Because the expression of NKCC1 and NPR-A in these regions were so segregated, the 
relationship between the two was clear, in that stimulation of K+ movement by NPR-A 
must be attributed to another protein or by diffusion of cGMP (or another messenger) 
across cell membranes.  Therefore it is unlikely NKCC1 becomes stimulated by the 
activation of NPR-A in root cells and basal cells.  Although it is unlikely that NKCC1 is 
the only effector in the ANP pathway, it is possible the secondary messengers may move 
between cells to stimulate the effector instead of along the same membrane. 
There are many other protein targets that could function as effectors following 
activation of NPR-A in the cochlear ANP pathway.  For cells in the spiral ligament, this 
could be an aquaporin or a potassium channel.  Zdebik et al. propose the movement of 
potassium ions into the fibrocytes is due to efflux by KCC3 in the root cells and uptake 
by Na+/K+ATPase in type III fibrocytes3.  For basal cells, NPR-A might influences the 
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connexins of the gap-junction networks to regulate the flow of K+ influx into the stria 
vascularis107. 
Another potential effector in the ANP pathway is aquaporin 6 (AQP6).  
Aquaporins are transmembrane channels responsible for the movement of water ions.  
AQP6 is a significant component of the kidney epithelium108,109.  Specifically, AQP6 is 
the only aquaporin found in renal podocytes (a region that expresses NPR-A), suggesting 
its potential role in glomerular filtration109.  In the inner ear, AQP6 expression has been 
shown in the interdental cells of the spiral limbus109 and along the luminal surface of the 
marginal cells in the stria vascularis110, both areas that express NPR-A. 
Conclusions 
These studies were designed to answer two main hypotheses: (1) NPR-A 
expression in the cochlea is in areas critical to fluid balance and K+ recycling and (2) 
NPR-A expression is co-localized to an effector protein, NKCC1, essential for K+ 
movement.  The first hypothesis was supported, while the second hypothesis was only 
partially supported, as co-localization with NKCC1 was intermittent or not present.  In 
the cochlea, NPR-A expression was observed in six specific cell types: interdental cells 
and limbal fibrocytes of the spiral limbus, root cells of the spiral ligament, basal and 
marginal cells of the stria vascularis, and spiral ganglion neurons.  NPR-A was clearly 
expressed in cells critical for the movement of K+, as these cells act as a gateway point 
for K+ efflux from a cellular system or influx into a cellular network.  NPR-A was 
expressed in two cell types (marginal cells of the stria vascularis and interdental cells of 
the spiral limbus) where K+ must exit a cellular network and re-enter the endolymph35.  
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Both conclusions indicate an essential role for the ANP pathway in the regulation of K+ 
transition during recycling. 
NPR-A was also expressed in type I spiral ganglion neurons, cells critical to 
carrying the sensory input stimulated by the inner hair cells.  While this finding was 
unexpected, NPR-A has been localized to other neurons important for functions such as 
nociception72 and itch response74 indicating a common importance of NPR-A in the 
regulation of sensory functions. 
The second hypothesis that NPR-A co-localizes with NKCC1 implicating the 
protein as a downstream effector in the ANP pathway was less definitively proven.  In 
both marginal cells and interdental cells, NKCC1 is a likely downstream target for NPR-
A because of the observed intermittent co-localization.  In these cells NPR-A could be 
acting both for K+ influx into the cells and K+ efflux into the endolymph, indicating the 
ANP cascade likely stimulates multiple effectors.  Unless cGMP diffuses between cells, 
clearly another effector must be activated in other cochlear cell types, as co-localization 
was not observed.  These areas include the spiral ligament root cells and fibrocytes and 
the basal cells of the stria vascularis.  In these two areas, NKCC1 was present in nearby 
cells, but did not co-localize with NPR-A indicating a need for another effector protein in 
the ANP cascade. 
In summary, NKCC1 does not appear to be the main effector stimulated by NPR-
A activation in the cochlea, as co-localization within individual cells was infrequent.  
However, there are numerous potassium channels, aquaporins, and other transporters in 
the cells of the cochlea that may act as potential downstream targets for NPR-A 
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secondary messengers.  NPR-A was expressed in cells acting as a gateway for K+ 
potentially signifying a critical role in K+ recycling and implicating other effectors in this 
pathway.  Furthermore due to the observed expression profiles, NPR-A likely stimulates 
transporters/channels for both influx and efflux of K+ from cells.  While future studies 
need to be performed to identify the proteins comprising the components of the ANP 
pathway, the results of this study provide novel information about where ANP may act in 
the cochlea.  
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